



David Escors Murugarren

Generated from: Editor CVN de FECYT

Date of document: 28/11/2020

v 1.4.3

13a4ea0fa02b5f79006b853171b41a11

This electronic file (PDF) has embedded CVN technology (CVN-XML). The CVN technology of this file allows you to export and import curricular data from and to any compatible data base. List of adapted databases available at: <http://cvn.fecyt.es/>



Summary of CV

This section describes briefly a summary of your career in science, academic and research; the main scientific and technological achievements and goals in your line of research in the medium -and long- term. It also includes other important aspects or peculiarities.

I am currently the Principal Investigator of the Immunomodulation group at Navarrabiomed, Spain. I founded my own independent research team in 2008 after being awarded the Arthritis Research UK fellowship. My group was integrated in the Division of Infection and Immunity, UCL. In 2013, I moved from UCL to the brand-new Navarrabiomed-Biomedical Research Centre, after obtaining a Miguel Servet Fellowship from the Institute of Health Carlos III, Spain. Amongst our achievements, we contributed to the discovery of the molecular mechanisms that regulate human T cell senescence (**Lanna et al. 2014. Nat Immunol; Lanna et al. 2017. Nat Immunol; Lanna et al. 2020. Nature Immunol, in press**). My research team also discovered one of the two main mechanisms of action of the potent anti-cancer antibodies that disrupt PDL1/PD1 interactions (**Karwacz et al. 2011. EMBO Mol Med; Liechtenstein et al. 2014. Oncolmunology; Zuazo et al. 2019. EMBO Mol Med**), and recently, the intracellular signaling domains of PD-L1 (**Gato-Canas et al. 2017. Cell Reports**), a very potent immunosuppressive regulator.

We maintain a strong high-quality publication output and frequently collaborate with top-researchers in immunology (**Prof Arne Akbar**, UCL; **Dr Clare Bennet**, UCL; **Prof Mary Collins**, currently in Okinawa Institute of Science and Technology; **Profs Karine Breckpot and Kris Thielemans**, Free University of Brussels). My research team is multidisciplinary and is currently composed of a senior scientist, 3 postdoctoral scientist, 2 PhD students and a lab technician. I have supervised 7 PhD students to completion, and I am currently supervising 2 PhD students.

**C****V****N**

CURRÍCULUM VITAE NORMALIZADO

13a4ea0fa02b5f79006b853171b41a11

General quality indicators of scientific research

This section describes briefly the main quality indicators of scientific production (periods of research activity, experience in supervising doctoral theses, total citations, articles in journals of the first quartile, H index...). It also includes other important aspects or peculiarities.

H-index, 37

Citations: 3968

89 indexed papers

David Escors Murugarren

Surname(s): **Escors Murugarren**
Name: **David**
ORCID: **0000-0003-2828-4458**

Current professional situation

Employing entity: FUNDACIÓN MIGUEL SERVET

Department: Oncology, Navarrabiomed

Professional category: Group leader

Start date: 18/03/2013

Type of contract: Permanent employment contract

Dedication regime: Full time

Performed tasks: The research group that I lead is interested in the study of antigen recognition by the immune system, during immune responses, and in cancer. We strongly focus on the translation of our results to clinical practice.

Employing entity: University College London, UK

Type of entity: University

Department: Infection and Immunity, Rayne Institute

Professional category: Honorary Senior Research Associate

Start date: 15/03/2013

Type of contract: Emeritus

Dedication regime: Full time

Primary (UNESCO code): 241200 - Immunology

Performed tasks: The research group that I lead is interested in the study of antigen recognition by the immune system, during immune responses, or in the establishment of immunological tolerance. We are applying our experimental results in the development of innovative immunotherapeutic therapies for the treatment of cancer (lymphoma and melanoma) and autoimmune diseases (rheumatoid arthritis).

Previous positions and activities

	Employing entity	Professional category	Start date
1	University College London, UK	Group leader	01/09/2008
2	University College London	Marie Curie post-doctoral fellow	01/07/2006
3	University College London	Post-doctoral fellow	01/02/2005
4	Consejo Superior de Investigaciones Científicas	Post-doctoral fellow	01/02/2002
5	Consejo Superior de Investigaciones Científicas	PhD student	01/07/1997

1 **Employing entity:** University College London, UK

Professional category: Group leader

Start-End date: 01/09/2008 - 14/03/2013



- 2** **Employing entity:** University College London **Type of entity:** University
Professional category: Marie Curie post-doctoral fellow
Start-End date: 01/07/2006 - 01/07/2008 **Duration:** 2 years
- 3** **Employing entity:** University College London
Professional category: Post-doctoral fellow
Start-End date: 01/02/2005 - 31/07/2006 **Duration:** 1 year
- 4** **Employing entity:** Consejo Superior de Investigaciones Científicas **Type of entity:** State agency
Professional category: Post-doctoral fellow
Start-End date: 01/02/2002 - 31/01/2005 **Duration:** 3 years
- 5** **Employing entity:** Consejo Superior de Investigaciones Científicas **Type of entity:** State agency
Professional category: PhD student
Start-End date: 01/07/1997 - 31/01/2002 **Duration:** 5 years



Education

University education

1st and 2nd cycle studies and pre-Bologna degrees

University degree: Higher degree

Name of qualification: BSc in Life Sciences

Degree awarding entity: Universidad de Navarra

Type of entity: University

Date of qualification: 30/06/1997

Prize: Special award for degree

Doctorates

Doctorate programme: Molecular Biology

Degree awarding entity: Universidad Autónoma de Madrid

Type of entity: University

Date of degree: 24/01/2002

Thesis director: Luis Enjuanes Sanchez

Obtained qualification: Cum Laude

Recognition of quality: Yes

Language skills

Language	Listening skills	Reading skills	Spoken interaction	Speaking skills	Writing skills
Spanish	C2	C2	C2	C2	C2
English	C2	C2	C2	C2	C2

Teaching experience

General teaching experience

- 1 Name of the course:** Molecular Virology

University degree: BSc in life sciences, medicine

Start date: 2009

Entity: University College London

Faculty, institute or centre: Division of Infection and Immunity

End date: 2012

Type of entity: University
- 2 Name of the course:** Frontiers in therapeutic development in infection and immunity

University degree: Master in Science

Start date: 2010

Entity: University College London

End date: 2011

Type of entity: University



Faculty, institute or centre: Division of Infection and Immunity

3 Name of the course: Advanced Genetics

University degree: Master

Entity: Universitat Autònoma de Barcelona

Type of entity: University

Experience supervising doctoral thesis and/or final year projects

1 Project title: Study on the functional role of LAG-3 in the dysfunctional signature of T cells

Entity: University of Navarre

Student: Luisa Chocarro de Erauso

Date of reading: 2022

2 Project title: Characterization of the molecular mechanisms of signal transduction by PD-1 and LAG-3

Type of project: Doctoral thesis

Entity: Universidad del País Vasco

Type of entity: University

Student: María Jesús García Granda

Date of reading: 2020

3 Project title: Overcoming T cell replicative senescence by interference with the PDL1-PD1 signalling pathway

Entity: Universidad Pública de Navarra

Type of entity: University

Student: Miren Zuazo Ibarra

Date of reading: 2020

4 Project title: Discovery of novel therapeutic targets in human pancreatic cancer by a systems biology-based selection technique

Entity: Universidad Pública de Navarra

Type of entity: University

Student: Hugo Arasanz Esteban

Date of reading: 2020

5 Project title: Summer Internship

Entity: University of Navarre

Type of entity: University

Student: Maria Serres

Date of reading: 31/07/2019

6 Project title: Summer internship

Entity: University of Navarre

Student: Pilar Morente

Date of reading: 31/07/2019

7 Project title: Development of soluble CD3-based immunological reagents

Type of project: End of course project

Entity: Vrije Universiteit Brussels

City of entity: Brusels, Belgium

Student: Julia Neumann

Date of reading: 2019

8 Project title: Study of two barriers in melanoma immunotherapy: Myeloid derived suppressor cells and PDL1/PD1 interaction

Entity: Universidad Pública de Navarra

Type of entity: University



Student: Maria Gato Cañas

Date of reading: 2019

- 9** **Project title:** Molecular tuning of telomerase activity in senescent human T cells
Entity: University College London **Type of entity:** University
Student: Alessio Lanna
Date of reading: 14/12/2015
- 10** **Project title:** Plasma membrane dynamics regulating the PD-1:PD-L1 pathway
Entity: University College London **Type of entity:** University
Student: Christopher Bricogne
Date of reading: 30/09/2015
- 11** **Project title:** AECC-funded BSc project: In vitro growth of B16 melanoma cell lines stably transformed with anti-oncogenic therapeutic genes
Entity: Asociación Española Contra el Cáncer **Type of entity:** Associations and Groups
Student: Estíbaliz Glaría
Date of reading: 04/09/2015
- 12** **Project title:** PhD thesis: Lentivector-based cancer immunotherapy silencing PD-L1 and modulating cytokine priming; Development of ex vivo myeloid-derived suppressor cells to assess therapeutic efficacy.
Entity: University College London **Type of entity:** University
Student: Therese Maria Liechtenstein
Date of reading: 18/05/2015
- 13** **Project title:** PhD thesis: Understanding the mechanisms of NF- κ B activation by viral oncoproteins vFLIP and Tax
Entity: University College London
Student: Mehdi Baratchian
Date of reading: 20/12/2014
- 14** **Project title:** Master in Science: Genetic modification of MDSCs for cancer immunotherapy
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Maria Gato Cañas
Date of reading: 2014
- 15** **Project title:** Master in Science: Genetic modification of dendritic cells for cancer immunotherapy
Entity: Universidad de Amsterdam **Type of entity:** University
Student: Therese Maria Liechtenstein
Date of reading: 30/06/2012
- 16** **Project title:** Master in Science: Engineering a DC-targeted lentivector for application in human gene therapy
Entity: Universidad de Bruselas, Belgica
Student: Ines Dufait
Date of reading: 31/05/2012
- 17** **Project title:** PhD thesis: Innate Immune Recognition of Glycosylated Surface Determinants of Campylobacter jejuni
Entity: University College London **Type of entity:** University
Student: Holly Stephenson
Date of reading: 31/03/2012



- 18** **Project title:** ECP: Development of dendritic cell-specific lentivectors for immunotherapy
Entity: Universidad de Bologna, Italia **Type of entity:** University
Student: Antonella Padella
Date of reading: 30/11/2011
- 19** **Project title:** ECP: Transcriptional regulation of TGF-beta in dendritic cells by targeted ERK activation
Entity: Universidad de Bologna, Italia
Student: Roberta Laranga
Date of reading: 30/11/2011
- 20** **Project title:** ECP: A novel mechanism for the regulation of T cell activation: PD-1 dependent early-brake model
Entity: University College London **Type of entity:** University
Student: Christopher Bricogne
Date of reading: 30/06/2011
- 21** **Project title:** Master in Science: Development of reporter lentivectors to assess pro-inflammatory and suppressive cytokine responses during Endoplasmic Reticulum (ER) stress
Entity: University College London **Type of entity:** University
Student: Anastasia Dimitriadi
Date of reading: 30/06/2011
- 22** **Project title:** ECP: Engineering DC-specific lentivectors by transcriptional targeting
Entity: Universidad de Cergy-Pontoise **Type of entity:** University
Student: Anais Lalliaume
Date of reading: 30/06/2010
- 23** **Project title:** ECP: Involvement of ERK, STAT3 and NF-kB signalling pathways in dendritic cell-induced antigen-specific immune-suppression
Entity: University College London **Type of entity:** University
Student: Li Fang
Date of reading: 30/06/2010
- 24** **Project title:** Master in Science: Inhibition of MAPK p38 signalling pathway in dendritic cells by genetic modification
Entity: University College London **Type of entity:** University
Student: Behnam Monzavi Tabrizi
Date of reading: 30/06/2010
- 25** **Project title:** Master in Science: Use of constitutive activators of immuno suppressive signalling pathways in lentivector vaccination
Entity: University College London **Type of entity:** University
Student: Stacey Trenchfield
Date of reading: 30/06/2010
- 26** **Project title:** ECP: Regulation of dendritic cell tolerogenic molecules by HIV-1- and MLV-based vectors
Entity: University College London **Type of entity:** University
Student: Kohmal Solanki
Date of reading: 30/06/2008



- 27** **Project title:** Master in Science: Dendritic cell activation by NF- κ B activation for cancer immunotherapy
Entity: University College London **Type of entity:** University
Student: Hema Byeajee
Date of reading: 30/06/2007
- 28** **Project title:** Master in Science: Dendritic cell activation by expression of HTLV Tax using lentivectors for cancer immunotherapy
Entity: University College London **Type of entity:** University
Student: Nataly Maimari
Date of reading: 30/06/2007

Student tutorials

Name of the programme: Educational aid
Entity: University College London **Type of entity:** University

Healthcare experience

Other activities/achievements not included above

- 1** **Other relevant activities:** Miguel Servet Fellow
Entity where project took place: FUNDACIÓN MIGUEL SERVET
End date: 2018
- 2** **Other relevant activities:** BD Bioscience 2014 immunology award
Entity where project took place: BD Bioscience **Type of entity:** Business
End date: 2014
- 3** **Other relevant activities:** Arthritis Research UK non-clinical Career Development Fellowship
Entity where project took place: University College London **Type of entity:** University
End date: 2013
- 4** **Other relevant activities:** Scientific reviewer of virology and immunology journals
Entity where project took place: University College London **Type of entity:** University
End date: 2012
- 5** **Other relevant activities:** UCL consultant, biotechnology companies
Entity where project took place: University College London **Type of entity:** University
End date: 2012
- 6** **Other relevant activities:** Marie Curie intra-european fellowship
Entity where project took place: University College London **Type of entity:** University
End date: 2008



- 7 Other relevant activities:** Scholaship for assitance to the IX Nidovirus international congress
Entity where project took place: Consejo Superior de Investigaciones Científicas
Type of entity: State agency
End date: 2003
- 8 Other relevant activities:** FPU Scholarship, from Ministerio de Educacion y Ciencia
Entity where project took place: Consejo Superior de Investigaciones Científicas
Type of entity: State agency
End date: 2002
- 9 Other relevant activities:** Scholaship for assitance to the XII International Congress of Virology
Entity where project took place: Consejo Superior de Investigaciones Científicas
Type of entity: State agency
End date: 2002
- 10 Other relevant activities:** Premio extraordinary fin de carrera (Award for BSc studies)
Entity where project took place: Universidad de Navarra
Type of entity: University
End date: 1997
- 11 Other relevant activities:** Scholarship for the introduction to scientific research, CSIC
Entity where project took place: Consejo Superior de Investigaciones Científicas
Type of entity: State agency
End date: 1997
- 12 Other relevant activities:** ERASMUS scholarship
Entity where project took place: University of Buckingham
Type of entity: University
End date: 1996
- 13 Other relevant activities:** PhD Jury member
- 14 Other relevant activities:** Project grant reviewer
Entity where project took place: EU, ANR, MRC, FWO
Type of entity: State agency

Scientific and technological experience

Scientific or technological activities

R&D projects funded through competitive calls of public or private entities

- 1** **Name of the project:** Horizon 2020. Improved vaccination for older adults (ISOLDA).
Entity where project took place: European Union **Type of entity:** Public Research Body
Name principal investigator (PI, Co-PI....): L Enjuanes; D Escors; A Osterhaus
Start-End date: 2020 - 2024
Total amount: 6.087.314,25 €
- 2** **Name of the project:** Platforms for the production of biosafe vaccines against SARS-CoV-2
Entity where project took place: FUNDACIÓN MIGUEL SERVET
City of entity: Pamplona, Foral Community of Navarre, Spain
Name principal investigator (PI, Co-PI....): R Reina; F Corrales; J Fernandez; E Santamaria; G Kochan; D Escors
Nº of researchers: 6
Start-End date: 31/05/2020 - 30/05/2021
Total amount: 115.000 €
- 3** **Name of the project:** Efectos de la senescencia inmunológica sobre la eficacia de las inmunoterapias anti-PDL1/anti-PD1
Entity where project took place: Fundación Miguel Servet
Name principal investigator (PI, Co-PI....): 1; D Escors
Nº of researchers: 10
Funding entity or bodies:
Asociación Española Contra el Cáncer **Type of entity:** Associations and Groups
City funding entity: Valencia, Valencian Community, Spain
Start-End date: 01/11/2017 - 01/11/2020
Total amount: 242.000 €
- 4** **Name of the project:** Impacto de la inmunoterapia anti-PDL1/anti-PD1 sobre las capacidades anti-tumorales de los linfocitos T humanos en diferentes estadios de diferenciación
Entity where project took place: FUNDACIÓN MIGUEL SERVET
Name principal investigator (PI, Co-PI....): D Escors; G Kochan
Nº of researchers: 9
Funding entity or bodies:
Instituto de Salud Carlos III **Type of entity:** Public Research Body
City funding entity: Majadahonda, Community of Madrid, Spain
Start-End date: 01/01/2018 - 2020
Total amount: 111.320 €
- 5** **Name of the project:** BioEusko Fundazioa: Identificación y explotación de nuevas dianas terapéuticas en células mieloides supresoras en sarcomas de Ewing metastásicos
Entity where project took place: FUNDACIÓN MIGUEL SERVET



City of entity: Pamplona, Foral Community of Navarre, Spain

Nº of researchers: 5

Start-End date: 2014 - 2017

Total amount: 91.953 €

- 6 Name of the project:** FIS project: Desarrollo de células mieloides supresoras en cáncer. Estudios epigenéticos, proteómicos y funcionales para la identificación de nuevas dianas terapéuticas

Entity where project took place: FUNDACIÓN MIGUEL SERVET

City of entity: Pamplona, Foral Community of Navarre, Spain

Name principal investigator (PI, Co-PI....): David Guerrero Setas

Nº of researchers: 4

Start-End date: 2014 - 2017

Total amount: 111.925 €

- 7 Name of the project:** Gobierno de Navarra: Desarrollo de una nueva generación de vacunas genéticas para el tratamiento de melanoma

Entity where project took place: FUNDACIÓN MIGUEL SERVET

City of entity: Pamplona, Foral Community of Navarre, Spain

Nº of researchers: 8

Start-End date: 2014 - 2017

Total amount: 52.881,6 €

- 8 Name of the project:** Biomedicine collaborative projects with biotechnology industries. ProCell

Entity where project took place: FUNDACIÓN MIGUEL SERVET

City of entity: Pamplona, Foral Community of Navarre, Spain

Name principal investigator (PI, Co-PI....): Grazyna Kochan; David Escors Murugarren

Nº of researchers: 2

Start-End date: 2015 - 2016

- 9 Name of the project:** Sandra Ibarra Foundation Award: Efectos de tratamientos anti-neoplásicos sobre la regulación epigenética, proteómica y funcional de las células mieloides supresoras en cáncer de mama.

Entity where project took place: FUNDACIÓN MIGUEL SERVET

City of entity: Pamplona, Foral Community of Navarre, Spain

Nº of researchers: 4

Start-End date: 2014 - 2016

Total amount: 20.000 €

- 10 Name of the project:** RefBio cooperation network

Entity where project took place: CIBIR, Navarrabiomed-FMS, CNRS, IACS

City of entity: La Rioja, La Rioja, Spain

Name principal investigator (PI, Co-PI....): Alfredo Martinez; Justin Teissie; David Escors Murugarren; Yolanda Gilaberte; Ignacio Larrayoz

Nº of researchers: 5

Start-End date: 15/10/2013 - 15/10/2014

Total amount: 21.000 €

- 11 Name of the project:** BD bioscience Immunology Spring 2014 award

Entity where project took place: FUNDACIÓN MIGUEL SERVET

City of entity: Pamplona, Foral Community of Navarre, Spain

Nº of researchers: 1

Start-End date: 2014 - 2014



Total amount: 7.750 €

- 12 Name of the project:** Induction of immunological tolerance by targeting intracellular signalling pathways in dendritic cells

Entity where project took place: University College London **Type of entity:** University

City of entity: Londres, Inner London, United Kingdom

Name principal investigator (PI, Co-PI....): David Escors Murugarren

Nº of researchers: 1

Funding entity or bodies:

Arthritis Research UK

Type of entity: Foundation

City funding entity: Londres, Inner London, United Kingdom

Start-End date: 2008 - 2013

Total amount: 614.398 €

- 13 Name of the project:** Volocity Software for 3D analysis and tracking and Dell Precision T7500 high specification computer

Entity where project took place: University College London **Type of entity:** University

City of entity: Londres, Inner London, United Kingdom

Name principal investigator (PI, Co-PI....): Natalie Carter; Anthony Antoniou; David Escors Murugarren; Claudia Mauri; Elizabeth Jury

Nº of researchers: 5

Funding entity or bodies:

Arthritis Research UK

Type of entity: Foundation

City funding entity: Londres, Inner London, United Kingdom

Start-End date: 2010 - 2012

Total amount: 11.938 €

- 14 Name of the project:** Marie Curie intra-european fellowship

Entity where project took place: University College London

City of entity: Londres, Inner London, United Kingdom

Name principal investigator (PI, Co-PI....): David Escors

Nº of researchers: 1

Funding entity or bodies:

Union Europea

Type of entity: State agency

Start-End date: 2006 - 2008

- 15 Name of the project:** Gobierno de Navarra. Proyectos de Biomedicina 2019. BMED 050-2019. Diseño y desarrollo de linfocitos T "inteligentes" que se adaptan para contrarrestar los efectos inhibitorios de la señalización por PD-1 y LAG-3 en el tumor (DDLIT).

Entity where project took place: Government of Navarre **Type of entity:** Public Research Body

City of entity: Pamplona, Foral Community of Navarre, Spain

Name principal investigator (PI, Co-PI....): G Fernandez; H Arasanz; D Escors

Start date: 2020

Total amount: 79.580 €

- 16** **Name of the project:** Independent Clinical Research Projects Call. Instituto de Salud Carlos III. TRANSPOCART.
Entity where project took place: Institute of Health **Type of entity:** State agency Carlos III
Name principal investigator (PI, Co-PI....): Consortium; D Escors; L Lopez
Start date: 2020
Total amount: 1.173.150 €
- 17** **Name of the project:** Desarrollo estratégico de terapias CART para el tratamiento de tumores hematológicos y sólidos (DESCARTES).
Entity where project took place: Strategic projects. Government of Navarre
Name principal investigator (PI, Co-PI....): Consortium; D Escors; JJ Lasarte
Start date: 2019
Total amount: 188.000 €
- 18** **Name of the project:** Zebrafish avatar as a real-time in-vivo platform for personalized cancer therapeutics
Entity where project took place: FUNDACIÓN MIGUEL SERVET
City of entity: Pamplona, Foral Community of Navarre, Spain
Name principal investigator (PI, Co-PI....): Other partners; David Escors; Roberto Díez Martínez
Nº of researchers: 12
Funding entity or bodies: European Union. Horizon 2020 **Type of entity:** Public Research Body
Start date: 2017
Total amount: 2.500.000 €
- 19** **Name of the project:** Vacunas que eliminan las "células escudo de los tumores"
Entity where project took place: FUNDACIÓN MIGUEL SERVET
City of entity: Pamplona, Foral Community of Navarre, Spain
Nº of researchers: 4
Funding entity or bodies: Fundación Española para la Ciencia y la Tecnología **Type of entity:** Fundación
City funding entity: Madrid, Community of Madrid, Spain
Start date: 2015
- 20** **Name of the project:** Miguel Servet Fellowship
Entity where project took place: FUNDACIÓN MIGUEL SERVET
City of entity: Pamplona, Foral Community of Navarre, Spain
Nº of researchers: 1
Funding entity or bodies: Instituto de Salud Carlos III **Type of entity:** Public Research Body
City funding entity: Majadahonda, Community of Madrid, Spain
Start date: 18/03/2013

R&D non-competitive contracts, agreements or projects with public or private entities

- 1** **Name of the project:** Desarmando el escudo protector del cáncer
Name principal investigator (PI, Co-PI....): D Escors
Funding entity or bodies:
SOCIEDAD ESPAÑOLA DE INMUNOLOGIA
City funding entity: Spain
Start date: 2019

- 2** **Name of the project:** Impact of PD-L1/PD-1 blockade on intracellular signalling pathways in human T cell populations undergoing tumour antigen recognition
Name principal investigator (PI, Co-PI....): G Kochan; D Escors
Funding entity or bodies:
Crescendo Biologics
City funding entity: Oxford, United Kingdom
Start date: 2017
Total amount: 154.650 €
Type of entity: Business
Duration: 2 years

- 3** **Name of the project:** Evaluation of the potentiation of radiotherapy following enzalutamide treatment in prostate cancer
Degree of contribution: Entidad financiadora
Name principal investigator (PI, Co-PI....): Fernando Arias De la Vega; Grazyna Kochan; David Escors Murugarren; David Guerrero Setas
Nº of researchers: 4
Funding entity or bodies:
Astellas Biotechnology
City funding entity: Tokio, Japan
Start date: 2015
Type of entity: Business

- 4** **Name of the project:** Discretionary funds, UCL
Degree of contribution: Researcher
Name principal investigator (PI, Co-PI....): David Escors Murugarren
Nº of researchers: 1
Funding entity or bodies:
University College London
City funding entity: Londres, Inner London, United Kingdom
Start date: 2011
Total amount: 4.800 €
Type of entity: University
Duration: 2 years

- 5** **Name of the project:** UCL consultant
Degree of contribution: Expert consultant
Name principal investigator (PI, Co-PI....): Mary Collins; David Escors Murugarren
Nº of researchers: 1
Funding entity or bodies:
Immune Targeting Systems (ITS) LTD
City funding entity: Londres, Inner London, United Kingdom
Start date: 2011
Duration: 1 year
Type of entity: Business



Total amount: 9.408 €

- 6** **Name of the project:** UCL funds
Degree of contribution: Researcher
Name principal investigator (PI, Co-PI....): David Escors Murugarren
Nº of researchers: 1
Funding entity or bodies:
University College London **Type of entity:** University
City funding entity: Londres, Inner London, United Kingdom
Start date: 2011 **Duration:** 2 years
Total amount: 11.702 €
- 7** **Name of the project:** UCL funds for supporting Master in Sciences Projects
Degree of contribution: Researcher
Name principal investigator (PI, Co-PI....): David Escors Murugarren
Nº of researchers: 1
Funding entity or bodies:
University College London **Type of entity:** University
City funding entity: Londres, Inner London, United Kingdom
Start date: 2010 **Duration:** 1 year
Total amount: 600 €

Results

Industrial and intellectual property

- 1** **Title registered industrial property:** Therapeutic molecules that bind LAG3 and PD1
Type of industrial property: Patent of invention **Author's rights:** Yes
Related rights: Yes **Trade secret:** Yes
Know-how: Yes
Inventors/authors/obtainers: Carolyn Edwards; Angelica Sette; Isobel Osuch; Yumin Teng; James Legg; David Escors Murugarren
Entity holder of rights: Crescendo Biologics Ltd
Nº of application: WO2019/158942 A1
Country of inscription: United Kingdom
Date of register: 22/08/2019
Spanish patent: No **EU patent:** Yes
PCT patent: Yes
Licences: Yes
Operating aut.region/region: Ecuador
- 2** **Title registered industrial property:** Method for generating suppressor cells
Inventors/authors/obtainers: David Escors Murugarren
Entity holder of rights: University College London
Nº of application: 14166221.3-1405
Country of inscription: Spain
Date of register: 2014



- 3 Title registered industrial property:** Patent: Nucleic acid sequence that contains an encapsidation signal from a group 1 coronavirus and its uses
Inventors/authors/obtainers: Javier Alonso; Luis Enjuanes; David Escors
Entity holder of rights: Consejo Superior de Investigaciones Científicas
Country of inscription: Spain, Community of Madrid
Date of register: 2004
Conferral date: 2007
- 4 Title registered industrial property:** Patent: Infective clones and vectors derived from coronavirus and its uses.
Inventors/authors/obtainers: Luis Enjuanes; Jose Maria Gonzalez; Zoltan Penzes; Fernando Almazan; Javier Ortego; Ander Izeta; Sara Alonso; David Escors; Cristina Riquelme; Enrique Calvo; Carlos Sanchez
Entity holder of rights: Consejo Superior de Investigaciones Científicas
Country of inscription: Spain, Community of Madrid
Date of register: 1999

Scientific and technological activities

Scientific production

Publications, scientific and technical documents

- 1** H Arasanz; M Zuazo; A Bocanegra; M Gato; M Martinez Aguillo; I Morilla; B Hernandez; P Lopez; N Alberdi; C Hernandez; L Chocarro; L Teijeira; R Vera; G Kochan; D Escors. Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. *Cancers (Basel)*. 12 - 2, pp. 344. 2020.
DOI: 10.3390/cancers12020344
PMID: 32033028
Type of production: Scientific paper
Position of signature: 15
Total no. authors: 15
Impact source: ISI
Impact index in year of publication: 6.102
Format: Journal
Corresponding author: Yes
Category: Oncology
Journal in the top 25%: Yes
Relevant publication: Yes
- 2** H Arasanz; C Hernandez; A Bocanegra; L Chocarro; M Zuazo; M Gato; K Ausin; E Santamaria; G Fernandez; E Santamaria; C Rodriguez; I Blanco; R Vera; D Escors; G Kochan. Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition. *Cancers*. 12 - 8, pp. 2181. 2020. ISSN 2072-6694
DOI: 10.3390/cancers12082181
Type of production: Scientific paper
Corresponding author: Yes
Impact source: ISI
Impact index in year of publication: 6.102
Format: Journal
Category: Oncology
Journal in the top 25%: Yes
Relevant publication: Yes
- 3** A Bocanegra; G Fernandez; M Zuazo; H Arasanz; MJ Garcia Granda; C Hernandez; M Ibañez; B Hernandez; M Martinez; MJ Lecumberri; A Fernandez; L Teijeira; I Morilla; R Vera; D Escors; G Kochan. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. *Int J Mol Sci*. 20 - 7, pp. E1631. 2019.

Type of production: Scientific paper
Position of signature: 15
Total no. authors: 16
Impact source: ISI
Impact index in year of publication: 4.198
Relevant publication: Yes

Format: Journal
Corresponding author: Yes
Category: Molecular biology
Journal in the top 25%: No

- 4** A Bocanegra; G Fernandez-Hinojal; M Zuazo-Ibarra; H Arasanz; MJ Garcia-Granda; C Hernandez; M Ibañez; B Hernandez-Marin; M Martinez-Aguillo; MJ Lecumberri; A Fernandez de Lascoiti; L Teijeira; I Morilla; R Vera; D Escors; G Kochan. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. *Int J Mol Sci.* 20, pp. pii: E1631.. 2019.

DOI: 10.3390/ijms20071631

PMID: 30986912

Type of production: Scientific paper
Position of signature: 15
Total no. authors: 15
Impact source: ISI
Impact index in year of publication: 3.6
Relevant publication: Yes

Format: Journal
Category: Molecular Biology

- 5** I Dufait; J Pardo; D Escors; Y De Vlaeminck; H Jiang; M Keyaerts; M De Ridder; K Breckpot. Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells. *Cancers.* 11, pp. pii: E808.. 2019.

Type of production: Scientific paper
Position of signature: 3
Total no. authors: 8
Impact source: SCOPUS
Impact index in year of publication: 5.326
Relevant publication: Yes

Category: Oncology
Journal in the top 25%: Yes

- 6** I Otano; D Escors; A Schurich; H Singh; F Robertson; BR Davidson; G Fusai; FA Vargas; ZMD Tan; JYJ Aw; N Hansi; PTF Kennedy; SA Xue; HJ Stauss; A Bertolotti; A Pavesi; MK Maini. Molecular recalibration of PD1+ antigen-specific T cells from blood and liver. *Mol Ther.* 26, pp. 2553 - 2566. 2018.

DOI: 10.1016/j.ymthe.2018.08.013

Type of production: Scientific paper
Position of signature: 2
Total no. authors: 18
Impact source: ISI
Impact index in year of publication: 6.938
Relevant publication: Yes

Format: Journal
Category: Molecular Medicine
Journal in the top 25%: Yes

- 7** A Lanna; DC Gomes; B Muller Durovic; T McDonnell; D Escors; DW Gilroy; JH Lee; M Karin; AN Akbar. A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging. *Nature Immunology.* 18, pp. 354 - 363. 2017. ISSN 1529-2908

DOI: 10.1038/ni.3665

Type of production: Scientific paper
Position of signature: 5
Total no. authors: 9
Impact source: ISI

Format: Journal
Category: Immunology

**Impact index in year of publication:** 20.004**Journal in the top 25%:** Yes**Relevant publication:** Yes

- 8** A Hotblack; L Zhang; S Hamrang Yousefi; R Chakraverty; D Escors; CL Bennett. Dendritic cells cross-present immunogenic lentiviral antigen from transduced cells to prime functional T cell immunity in vaccinated mice. *Mol Ther.* 25 - 2, pp. 504 - 511. 2017.

DOI: 10.1016/j.ymthe.2016.11.001.**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 5**Total no. authors:** 6**Impact source:** ISI**Category:** Molecular Medicine**Impact index in year of publication:** 6,938**Journal in the top 25%:** Yes**Relevant publication:** Yes

- 9** M Gato Cañas; M Zuazo; H Arasan; M Ibañez Veja; L Lorenzo; G Fernandez Hinojal; R Vera; C Smerdou; E Martisova; I Arozarena; C Wellbrock; D Llopiz; M Ruiz; P Sarobe; K Breckpot; G Kochan; D Escors. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. *Cell Rep.* 20, pp. 1818 - 1829. Cell Press, 2017.

DOI: 10.1016/j.celrep.2017.07.075**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 17**Total no. authors:** 17**Impact source:** ISI**Corresponding author:** Yes**Category:** Biological sciences**Impact index in year of publication:** 8.282**Journal in the top 25%:** Yes**Relevant publication:** Yes

- 10** M Gato Cañas; X Martinez de Morentin; I Blanco Luquin; J Fernandez Irigoyen; I Zudaire; T Liechtenstein; H Arasan; T Lozano; N Casares; A Chaikuad; S Knapp; D Guerrero Setas; D Escors; G Kochan; E Santamaria. A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. *Oncotarget.* 6, pp. 27160. 2015.

Type of production: Scientific paper**Format:** Journal**Position of signature:** 13**Total no. authors:** 15**Impact source:** ISI**Corresponding author:** Yes**Category:** Oncology**Impact index in year of publication:** 6.359**Journal in the top 25%:** Yes**Relevant publication:** Yes

- 11** K Sanber; S Knight; S Stephen; R Bailey; D Escors; J Minshull; G Santilli; A Thrasher; M Collins; Y Takeuchi. Construction of stable packaging cell lines for clinical lentiviral vector production. *Scientific Reports.* 5, pp. 9021. 2015. ISSN 2045-2322

DOI: 10.1038/srep09021**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 5**Total no. authors:** 10**Impact source:** ISI**Corresponding author:** No**Category:** natural and clinical science**Impact index in year of publication:** 5.228**Journal in the top 25%:** Yes**Relevant publication:** Yes

- 12** I Dufait; JK Schwarze; T Liechtenstein; W Leonard; H Jiang; D Escors; M De Ridder; K Breckpot. Ex vivo generation of myeloid-derived suppressor cells that model the tumour immunosuppressive environment in colorectal cancer. *Oncotarget*. 6, pp. 12369. 2015.
Type of production: Scientific paper **Format:** Journal
Position of signature: 6
Total no. authors: 8 **Corresponding author:** No
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 6.359 **Journal in the top 25%:** Yes
Relevant publication: Yes
- 13** T Liechtenstein; N Perez Janices; M Gato; F Caliendo; G Kochan; I Blanco Luquin; F Arce; D Guerrero Setas; J Fernandez Irigoyen; E Santamaria; K Breckpot; D Escors. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. *Oncotarget*. 5, pp. 7843 - 7857. 2014.
Type of production: Scientific paper **Format:** Journal
Position of signature: 12
Total no. authors: 12 **Corresponding author:** Yes
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 6.359 **Journal in the top 25%:** Yes
Relevant publication: Yes
- 14** T Liechtenstein; N Perez Janices; I Blanco Luquin; J Schwarze; I Dufait; A Lanna; M De Ridder; D Guerrero Setas; K Breckpot; D Escors. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. *Oncotarget*. 2014.
Type of production: Scientific paper **Format:** Journal
Position of signature: 10
Total no. authors: 10 **Corresponding author:** Yes
Impact source: ISI **Category:** Immunology
Impact index in year of publication: 6.266 **Journal in the top 25%:** Yes
Relevant publication: Yes
- 15** A Lanna; S Henson; D Escors; A Akbar. The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. *Nature Immunology*. 15, pp. 965 - 972. 2014. ISSN 1529-2908
DOI: 10.1038/ni.2981
Type of production: Scientific paper **Format:** Journal
Position of signature: 3
Total no. authors: 4 **Corresponding author:** Yes
Impact source: ISI **Category:** Immunology
Impact index in year of publication: 20.004 **Journal in the top 25%:** Yes
Relevant publication: Yes
- 16** Katarzyna Karwacz; Christopher Bricogne; Douglas MacDonald; Frederick Arce; Clare Bennett; Mary Collins; David Escors. PD-L1 co-stimulation contributes to T cell receptor down-modulation on CD8 T cells. *EMBO Molecular Medicine*. 3 - 10, pp. 581 - 592. WILEY-VCH Verlag, 10/08/2011.
Type of production: Scientific paper **Format:** Journal
Position of signature: 7
Total no. authors: 7 **Corresponding author:** Yes
Impact source: ISI **Category:** Molecular Medicine

Impact index in year of publication: 10.333**Journal in the top 25%:** Yes**Relevant publication:** Yes

- 17** Frederick Arce; Karine Breckpot; Holly Stephenson; Katarzyna Karwacz; Michael Ehrenstein; Mary Collins; David Escors. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. *Arthritis and Rheumatism*. 63 - 1, pp. 84 - 95. Wiley Subscription Services, Inc., A Wiley Company, 01/01/2011.

Type of production: Scientific paper**Format:** Journal**Position of signature:** 7**Total no. authors:** 7**Corresponding author:** Yes**Impact source:** ISI**Category:** Medicine (miscellaneous)**Impact index in year of publication:** 7.866**Journal in the top 25%:** Yes**Relevant publication:** Yes

- 18** David Escors; Luciene Lopes; Rongtuan Lin; John Hiscott; Shizuo Akira; Roger J Davis; Mary Collins. Targeting dendritic cell signaling to regulate the response to immunization. *Blood*. 111 - 6, pp. 3050 - 3061. American Society of Hematology, 15/03/2008.

Type of production: Scientific paper**Format:** Journal**Impact source:** ISI**Category:** Medicine (miscellaneous)**Impact index in year of publication:** 10.432**Journal in the top 25%:** Yes**Relevant publication:** Yes

- 19** G Traini; A Ruiz de Angulo; JB Blanco-Canosa; K Zamacola; A Molinaro; A Silipo; D Escors; JC Mareque-Rivas. Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1. *Small*. 2019. ISSN 1613-6829

DOI: 10.1002/smll.201803993**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 7**Total no. authors:** 8**Impact source:** ISI**Category:** Molecular medicine**Impact index in year of publication:** 9.598**Journal in the top 25%:** Yes

- 20** M Zuazo; H Arasanz; G Fernandez-Hinojal; MJ Garcia-Granda; M Gato; A Bocanegra; M Martinez; B Hernandez; L Teixeira; I Morilla; MJ Lecumberri; AF de Lascoiti; R Vera; G Kochan; D Escors. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. *EMBO Mol Med*. pii: e10293., Wiley, 2019.

Type of production: Scientific paper**Format:** Journal**Position of signature:** 15**Total no. authors:** 15**Corresponding author:** Yes**Impact source:** ISI**Category:** Molecular Medicine**Impact index in year of publication:** 10.293**Journal in the top 25%:** Yes

- 21** M Barrado; I Blanco-Luquin; PA Navarrete; I Visus; D Guerrero-Setas; D Escors; G Kochan; F Arias. Radiopotential of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring. *Rep Pract Oncol Radiother*. 24, pp. 221 - 226. 2019.

DOI: 10.1016/j.rpor.2019.02.002**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 6**Total no. authors:** 8

- 22** MC Ballesteros-Briones; E Martisova; E Casales; N Silva-Pilipich; M Buñuales; J Galindo; U Mancheño; M Gorraiz; JJ Lasarte; G Kochan; D Escors; AR Sanchez-Paulete; I Melero; J Prieto; R Hernandez-Alcoceba; S Hervas-Stubbs; C Smerdou. Short-term local expression of a PD-L1 blocking antibody from a self-replicating RNA vector induces potent antitumor responses. *Mol Ther.* 27 - 11, pp. 1892 - 1905. 2019.
Type of production: Scientific paper
Position of signature: 11
Total no. authors: 17
- 23** M Ibáñez Vea; H Huang; X Martínez de Morentín; E Pérez; M Gato; M Zuazo; H Arasanz; J Fernández Irigoyen; E Santamaría; G Fernández Hinojal; MR Larsen; D Escors; G Kochan. Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO₂ Chromatography. *J Proteome Res.* 25/01/2018.
DOI: 10.1021/acs.jproteome.7b00812
Type of production: Scientific paper
Position of signature: 12
Total no. authors: 13
Impact source: ISI
Impact index in year of publication: 4.268
Format: Journal
Category: Proteómica
Journal in the top 25%: Yes
- 24** AI Bocanegra Gondan; A Ruiz-de-Angulo; A Zabaleta; N Gomez Blanco; BM Cobaleda-Siles; MJ Granda; D Padro; J Llop; B Arnaiz; M Gato; D Escors; JC Mareque Rivas. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles. *Biomaterials.* 170, pp. 95 - 115. 2018.
DOI: 10.1016/j.biomaterials.2018.04.003
Type of production: Scientific paper
Position of signature: 11
Total no. authors: 12
Impact source: ISI
Impact index in year of publication: 8.402
Format: Journal
Category: Medicine
Journal in the top 25%: Yes
- 25** D Escors; M Gatto-Cañas; M Zuazo; H Arasanz; MJ Garcia-Granda; R Vera; G Kochan. The intracellular signalosome of PD-L1 in cancer cells. *Signal Transduct Target Ther.* 3, pp. 26. 2018.
Type of production: Scientific paper
Position of signature: 1
Total no. authors: 7
Format: Journal
- 26** C Goyvaerts; Y De Vlaeminck; D Escors; S Lienenkalus; M Keyaerts; G Raes; K Breckpot. Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery. *Gene Ther.* 24, pp. 370 - 375. 2017.
Type of production: Scientific paper
Position of signature: 3
Total no. authors: 7
Format: Journal
- 27** E Martine Sanchez; S Mendaza; A Ulazia Garmendia; I Monreal Santesteban; I Blanco Luquin; A Cordoba; F Vicente Garcia; N Perez Janices; D Escors; D Megias; JJ Illarramendi; D Guerrero Setas. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer. *Oncotarget.* doi: 10.18632/oncotarget, 2017.
Type of production: Scientific paper
Position of signature: 9
Total no. authors: 12
Impact source: ISI
Impact index in year of publication: 6.359
Format: Journal
Category: Oncology
Journal in the top 25%: Yes



- 28** K Broos; M Keyaerts; Q Lecocq; D Renmans; T Nguyen; D Escors; A Liston; G Raes; K Breckpot; N Devoogdt. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. *Oncotarget*. 8, pp. 41932 - 41946. 2017.
Type of production: Scientific paper
Position of signature: 6
Total no. authors: 10
Impact source: ISI
Impact index in year of publication: 5.168
Category: Oncology
Journal in the top 25%: Yes
- 29** M Baratchian; CA Davis; A Shimizu; D Escors; C Bagneris; T Barrett; MK Collins. Distinct activation mechanisms of NF- κ B regulator IKK by isoforms of the cell death regulator cFLIP. *J Biol Chem*. 291, pp. 7608. 2016.
Type of production: Scientific paper
Position of signature: 4
Total no. authors: 7
Impact source: ISI
Impact index in year of publication: 4.258
Format: Journal
Category: Biochemistry
Journal in the top 25%: Yes
- 30** E Martin Sanchez; E Pernaut Leza; S Mendaza; A Cordoba; F Vicente Garcia; I Moreal Santesteban; JP Vizcaino; MJ De Cerio; N Perez Janices; I Blanco Luquin; D Escors; A Ulazia Garmendia; D Guerrero Setas. Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA. *Virchows Arch*. 469, pp. 51. 2016.
Type of production: Scientific paper
Position of signature: 11
Total no. authors: 13
Impact source: ISI
Impact index in year of publication: 2.65
Format: Journal
- 31** L Mantoan Ritter; DC MacDonald; G Ritter; D Escors; F Chiara; A Cariboni; S Schorge; DM Kullmann; M Collins. Lentiviral expression of GAD67 and CCK promoter-driven opsins to target interneurons in vitro and in vivo. *J Gene Med*. 18, pp. 27. 2016.
Type of production: Scientific paper
Position of signature: 4
Total no. authors: 9
Impact source: ISI
Impact index in year of publication: 2.472
Format: Journal
- 32** W Leonard; I Dufait; J Schwarze; K Law; B Engels; H Jiang; D Van den Berghe; T Gevaert; G Storme; V Verovski; K Breckpot; M De Ridder. Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced L-arginine depletion. *Radiother Oncol*. 167, pp. 8140(16)00045-1. 2016.
Type of production: Scientific paper
Format: Journal
- 33** N Perez Janices; I Blanco Luquin; N Torrea; T Liechtenstein; D Escors; A Cordoba; F Vicente Garcia; I Jauregui; S De la Cruz; JJ Illarramendi; V Coca; M Berdasco; G Kochan; B Ibañez; JM Lero; David Guerrero Setas. Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. *Oncotarget*. 6, pp. 23944. 2015.
Type of production: Scientific paper
Position of signature: 5
Total no. authors: 16
Impact source: ISI
Format: Journal
Category: Oncology

**Impact index in year of publication:** 6.359**Journal in the top 25%:** Yes

- 34** I Blanco Luquin; R Guarch; A Ojer; N Perez Janices; E Martin Sanchez; S Maria Ruiz; I Moreal Santesteban; L Blanco Fernandez; E Pernaut Leza; D Escors; D Guerrero Setas. Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix. *Pathol. Int.* 65, pp. 476. 2015.

Type of production: Scientific paper**Format:** Journal**Position of signature:** 10**Total no. authors:** 11**Impact source:** ISI**Impact index in year of publication:** 1.425

- 35** N Perez Janices; I Blanco Luquin; MT Tuñón; E Barba Ramos; B Ibañez; I Zazpe Cenoz; M Martinez Aguillo; B Hernandez; E Martinez Lopez; AF Fernandez; MR Mercado; T Cabada; D Escors; D Megias; D Guerrero Setas. EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. *Oncotarget*. 6, pp. 368 - 380. 2015.

Type of production: Scientific paper**Format:** Journal**Position of signature:** 13**Total no. authors:** 15**Impact source:** ISI**Impact index in year of publication:** 6.359**Corresponding author:** No**Category:** Oncology**Journal in the top 25%:** Yes

- 36** C Goyvaerts; K Broos; D Escors; C Heirman; G Raes; P De Baetselier; K Thielemans; K Breckpot. The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome. *Eur J Immunol*. 45, pp. 3351. 2015.

Type of production: Scientific paper**Format:** Journal**Position of signature:** 3**Total no. authors:** 8**Impact source:** ISI**Impact index in year of publication:** 4.179**Category:** Immunology**Journal in the top 25%:** Yes

- 37** I Dufait; J Schwarze; T Liechtenstein; W Leonard; H Jiang; D Escors; M De Ridder; K Breckpot. ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. *Oncotarget*. 6, pp. 12369. 2015.

Type of production: Scientific paper**Position of signature:** 6**Total no. authors:** 8

- 38** T Liechtenstein; N Perez Janices; I Blanco Luquin; G goyvaerts; J Schwarze; I Dufait; A Lanna; M De Ridder; D Guerrero Setas; K Breckpot; D Escors. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. *Oncolmmunology*. 3, pp. e945378.. 2014.

DOI: 10.4161/21624011.2014.945378**Type of production:** Scientific paper**Format:** Journal**Position of signature:** 11**Total no. authors:** 11**Corresponding author:** Yes



- 39** D McDonald; H Singh; MA Whelan; D Escors; F Arce; SE Bottoms; WS Barclay; M Maini; MK Collins; WMC Rosenberg. Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. *Mucosal Immunology*. 7, pp. 89 - 100. 2014. ISSN 1935-3456
DOI: 10.1038/mi.2013.27.
Type of production: Scientific paper
Position of signature: 4
Total no. authors: 10
Impact source: ISI
Impact index in year of publication: 7.374
Corresponding author: No
Category: Immunology
Journal in the top 25%: Yes
- 40** J Pen; B De Keersmaecker; C Heirman; J Corthals; T Liechtenstein; D Escors; K Thielemans; K Breckpot. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. *Gene Therapy*. 21, pp. 262 - 271. 2014.
Type of production: Scientific paper
Position of signature: 6
Total no. authors: 8
Impact source: ISI
Impact index in year of publication: 3.104
Format: Journal
Corresponding author: No
Category: Molecular Medicine
Journal in the top 25%: Yes
- 41** K Van der Jeught; PT Joe; L Bialkowski; C Heirman; L Daszkiewicz; T Liechtenstein; D Escors; K Thielemans; K Breckpot. Intratumoral administration of mRNA encoding a fusokine consisting of IFN- γ and the ectodomain of the TGF- β receptor II potentiates antitumor immunity. *Oncotarget*. 5, pp. 10100 - 10113. 2014.
Type of production: Scientific paper
Position of signature: 7
Total no. authors: 9
Impact source: ISI
Impact index in year of publication: 6.359
Format: Journal
Category: Oncology
Journal in the top 25%: Yes
- 42** Hester A Franks; Q Wang; SJ Lax; MK Collins; David Escors Murugarren; PM Patel; P Jackson. Novel function for the p38-MK2 signaling pathway in circulating CD1c⁺ (BDCA-1⁺) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL10. *Int J Cancer*. 134, pp. 575 - 586. 2014.
DOI: 10.1002/ijc.28398
PMID: 23901045
Type of production: Scientific paper
Position of signature: 5
Total no. authors: 7
Impact source: ISI
Impact index in year of publication: 5.085
Corresponding author: No
Category: Cancer Research
Journal in the top 25%: Yes
- 43** HN Stephenson; DC Mills; H Jones; E Milioris; A Copland; N Dorrell; BW Wren; PR Crocker; D Escors; M Bajaj-Elliott. Pseudoaminic acid on *Campylobacter jejuni* flagella modulates dendritic cell IL-10 expression via siglec-10 receptor: a novel flagellin-host interaction. *Journal of Infectious Diseases*. pii: jiu287, 2014.
Type of production: Scientific paper
Position of signature: 9
Total no. authors: 10
Impact source: ISI
Impact index in year of publication: 6.344
Format: Journal
Category: Molecular Medicine
Journal in the top 25%: Yes

- 44** J Campos Perez; J Rice; D Escors Murugarren; M Collins; A Paterson; N Savelyeva; FK Stevenson. DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1. *Int J Cancer*. doi: 10.1002/ijc.281, 2013.
Type of production: Scientific paper **Format:** Journal
Position of signature: 3
Total no. authors: 7
Impact source: ISI **Category:** Cancer Research
Impact index in year of publication: 5.007 **Journal in the top 25%:** Yes
- 45** J Pen; B De Keersmaecker; S Maenhout; A Van Nuffel; C Heirman; J Corthals; D Escors; A Bonehill; K Thielemans; K Breckpot; J L Aerts. Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4 and CD70. *Journal of Immunology*. 191, pp. 1976 - 1983. 2013.
Type of production: Scientific paper
Position of signature: 7
Total no. authors: 10
Impact source: ISI **Category:** Immunology
Impact index in year of publication: 5.362 **Journal in the top 25%:** Yes
- 46** Akira Shimizu; Mehdi Baratchian; Yasu Takeuchi; David Escors; Douglas MacDonald; Tracey Barrett; Claire Bagneris; Mary Collins; Mahdad Noursadeghi. KSHV vFLIP and HTLV1 Tax oncogenic proteins activate IKK γ by different mechanisms independent of physiological cytokine-induced pathways. *Journal of Virology*. 85 - 14, pp. 7444 - 7448. American Society for Microbiology, 18/05/2011.
Type of production: Scientific paper **Format:** Journal
Position of signature: 4
Total no. authors: 9
Impact source: ISI **Category:** Virology
Impact index in year of publication: 5.402 **Journal in the top 25%:** Yes
- 47** Hugh D Goold; David Escors; Thomas J Conlan; Ronjon Chakraverty; Clare L Bennett. Conventional Dendritic Cells Are Required for the Activation of Helper-Dependent CD8 T Cell Responses to a Model Antigen After Cutaneous Vaccination with Lentiviral Vectors. *Journal of Immunology*. 186 - 8, pp. 4565 - 4572. American Association of Immunologists, 15/04/2011.
Type of production: Scientific paper **Format:** Journal
Position of signature: 2
Total no. authors: 5
Impact source: ISI **Category:** Immunology
Impact index in year of publication: 5.788 **Journal in the top 25%:** Yes
- 48** Karine Breckpot; David Escors; Frederick Arce; Lucienne Lopes; Katarzyna Karwacz; Sandra Van Lint; Marleen Keyaerts; Mary Collins. HIV-1 lentiviral vector immunogenicity is mediated by TLR3 and TLR7. *Journal of Virology*. 84 - 11, pp. 5627 - 5636. American Society for Microbiology, 01/06/2010.
Type of production: Scientific paper **Format:** Journal
Position of signature: 2
Total no. authors: 8
Impact source: ISI **Category:** Virology
Impact index in year of publication: 5.189 **Journal in the top 25%:** Yes

- 49** Mario Perro; J Tsang; SA Xue; David Escors; M Cesco-Gaspere; C Pospori; L Gao; D Hart; Mary Collins; Hans Stauss; EC Morris. Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Therapy. pp. 721 - 732. Nature Publishing Group, 18/02/2010.
Type of production: Scientific paper **Format:** Journal
Position of signature: 4
Total no. authors: 11
Impact source: ISI **Category:** Molecular Medicine
Impact index in year of publication: 4.538 **Journal in the top 25%:** Yes
- 50** Katarzyna Karwacz; Sayandip Mukherjee; Luis Apolonia; Michael P Blundell; Gerben Bouma; David Escors; Mary K Collins; Adrian J Thrasher. Non-integrating lentivector vaccines stimulate prolonged T cell and antibody responses and are effective in tumor therapy. Journal of Virology. 83 - 7, pp. 3094 - 3103. American Society for Microbiology, 01/04/2009.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Virology
Impact index in year of publication: 5.15 **Journal in the top 25%:** Yes
- 51** Grazyna Kochan; David Escors; Jose Manuel Gonzalez; Jose Maria Casasnovas; Mariano Esteban. Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cellular Microbiology. 10 - 1, pp. 149 - 164. Blackwell Publishing Ltd, 01/01/2008.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Microbiology
Impact index in year of publication: 5.598 **Journal in the top 25%:** Yes
- 52** Clare Selden; Neil Mellor; Myrddin Rees; Joanna Laurson; Mike Kirwan; David Escors; Mary Collins; Humphrey Hodgson. Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. The journal of gene medicine. 9 - 2, pp. 67 - 76. John Wiley & Sons, Ltd., 01/02/2007.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI
Impact index in year of publication: 3.141
- 53** Fernando Almazan; Marta L DeDiego; Carmen Galan; David Escors; Enrique Alvarez; Javier Ortego; Isabel Sola; Sonia Zuñiga; Sara Alonso; Jose Luis Moreno; Aitor Nogales; Carmen Capiscol; Luis Enjuanes. Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. Journal of Virology. 80 - 21, pp. 10900 - 10906. American Society for Microbiology, 01/11/2006.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Virology
Impact index in year of publication: 5.97 **Journal in the top 25%:** Yes
- 54** Enrique Calvo; David Escors; JA Lopez; Jose Manuel Gonzalez; A Alvarez; E Arza; Luis Enjuanes. Phosphorylation and subcellular localisation of transmissible gastroenteritis virus nucleocapsid protein. Journal of general virology. 86 - 8, pp. 2255 - 2267. Society for General Microbiology, 01/08/2005.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI
Impact index in year of publication: 3.03

- 55** Christel Schwegmann-Wessels; Marwan Al-Falah; David Escors; Zai Wang; Gert Zimmer; Hongkui Deng; Luis Enjuanes; Hassan Y Naim; Georg Herrler. A novel sorting signal for intracellular localization is present in the S protein of a porcine coronavirus but absent from SARS-associated coronavirus. *Journal of Biological Chemistry*. 279 - 42, pp. 43661 - 43666. 15/10/2004.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Biochemistry
Impact index in year of publication: 6.57 **Journal in the top 25%:** Yes
- 56** David Escors; Carmen Capiscol; Luis Enjuanes. Immunopurification applied to the study of virus protein composition and encapsidation. *Journal of virological methods*. 119 - 2, pp. 57 - 64. 31/08/2004.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI
Impact index in year of publication: 2.17
- 57** David Escors; Ander Izeta; Carmen Capiscol; Luis Enjuanes. Transmissible gastroenteritis coronavirus packaging signal is located at the 5' end of the virus genome. *Journal of Virology*. 77 - 14, pp. 7890 - 7902. American Society for Microbiology, 15/07/2003.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Virology
Impact index in year of publication: 5.73 **Journal in the top 25%:** Yes
- 58** Javier Ortego; David Escors; Hubert Laude; Luis Enjuanes. Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome. *Journal of Virology*. 76 - 22, pp. 11518 - 11529. American Society for Microbiology, 15/11/2002.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Virology
Impact index in year of publication: 5.54 **Journal in the top 25%:** Yes
- 59** Cristina Riquelme; David Escors; Javier Ortego; Carlos M Sanchez; Branislava Uzelac-Keserovic; Konstantin Apostolov; Luis Enjuanes. Nature of the virus associated to the endemic balkan nephropathy. *Emerging infectious diseases*. 8 - 8, pp. 869 - 869. Centers for Disease Control, 01/08/2002.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Medicine (miscellaneous)
Impact index in year of publication: 6 **Journal in the top 25%:** Yes
- 60** David Escors; Emilio Camafeita; Javier Ortego; Hubert Laude; Luis Enjuanes. Organization of two transmissible gastroenteritis coronavirus membrane protein topologies within the virion and core. *Journal of Virology*. 75 - 24, pp. 12228 - 12240. American Society for Microbiology, 15/12/2001.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Virology
Impact index in year of publication: 5.54 **Journal in the top 25%:** Yes
- 61** David Escors; Javier Ortego; Hubert Laude; Luis Enjuanes. The membrane M protein carboxy-terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability. *Journal of Virology*. 75 - 3, pp. 1312 - 1324. American Society for Microbiology, 01/02/2001.
Type of production: Scientific paper **Format:** Journal
Impact source: ISI **Category:** Virology
Impact index in year of publication: 5.54 **Journal in the top 25%:** Yes

- 62** D Escors. Envejecimiento del sistema inmunitario. Investigación y Ciencia (Scientific American). 460, 2015.
Type of production: Popular science article **Format:** Journal
Corresponding author: Yes
- 63** David Escors; Luis Enjuanes. Las enfermedades virales emergentes: el coronavirus del síndrome respiratorio agudo y severo. Historia Natural. ISSN: 16966341, pp. 48 - 52. sociedad española historia natural, 2003.
Type of production: Popular science article **Format:** Book
Corresponding author: Yes
- 64** Ines Dufait; Therese Liechtenstein; Alessio Lanna; Roberta Laranga; Antonella Padella; Christopher Bricogne; Frederick Arce; Grazyna Kochan; Karine Breckpot; David Escors. Lentiviral vectors in immunotherapy. Gene Therapy. Tools and Potential applications. IntechOpen, 2013.
Type of production: Book chapter **Format:** Book
Corresponding author: Yes
- 65** C Goyvaerts; T Liechtenstein; C Bricogne; D Escors; K Breckpot. Targeted lentiviral vectors: current applications and future potential. Gene Therapy. Tools and Potential applications. . IntechOpen, 2013.
Type of production: Book chapter
Corresponding author: Yes
- 66** Christopher Bricogne; Roberta Laranga; Antonella Padella; Ines Dufait; Therese Liechtenstein; Karine Breckpot; Grazyna Kochan; David Escors. Critical mass hypothesis of T cell responses and its application for the treatment of T cell lymphoma. T cell lymphoma. ISBN: 978-1-62257-50, NOVA Publishers, 2012.
Type of production: Book chapter **Format:** Book
Corresponding author: Yes
- 67** Cleo Goyvaerts; Grazyna Kochan; David Escors; Karine Breckpot. Dendritic cells and lentiviral vectors: mapping the way to successful immunotherapy. Viral Gene Therapy. pp. 309 - 352. InTech, 2011.
Type of production: Book chapter **Format:** Book
Corresponding author: Yes
- 68** Luis Enjuanes; Isabel Sola; Sara Alonso; David Escors; Sonia Zúñiga. Coronavirus reverse genetics and development of vectors for gene expression. Coronavirus replication and reverse genetics. Current Topics in Microbiology and Immunology. 287, pp. 161 - 197. Springer Verlag, 2004.
Type of production: Book chapter **Format:** Book
- 69** Luis Enjuanes; Fernando Almazan; Isabel Sola; Javier Ortego; Sara Alonso; Sonia Zúñiga; David Escors. Coronavirus reverse genetics and development of vaccine vectors based on transmissible gastroenteritis coronavirus genomes. Impact of genomics in new technologies. pp. 5 - 14. Valencian's foundation of advanced studies, 2003.
Type of production: Book chapter **Format:** Book
- 70** L Enjuanes; I Sola; F Almazan; J Ortego; Sara Alonso; JM Gonzalez; JM Sanchez-Morgado; A Izeta; David Escors; CM Sanchez; E Calvo; C Riquelme; P Barrado; M Balasch; J Plana-Durán. Interference with viral infection by transgenesis or tissue specific expression. Molecular Farming. pp. 39 - 51. Proceedings of the OECD Workshop, 2001.
Type of production: Book chapter **Format:** Book
- 71** David Escors; Javier Ortego; Luis Enjuanes. The membrane protein of the TGEV interacts with the core through the carboxy-terminus. NIDOVIRUSES (CORONAVIRUSES AND ARTERIVIRUSES). 494, pp. 589 - 593. KLUWER ACADEMIC/PLENUM PUBL, 2001.
Type of production: Book chapter **Format:** Book



- 72** Luis Enjuanes; Isabel Sola; Ander Izeta; Jose M Sanchez-Morgado; Jose M Gonzalez; Sara Alonso; David Escors; Carlos M Sanchez. Interference with virus and bacteria replication by the tissue specific expression of antibodies and interfering molecules. *Advances in Experimental Medicine and Biology*. 473, pp. 31 - 46. New York, Plenum Press, 1967-, 1999.

Type of production: Book chapter

Format: Book

- 73** Luis Enjuanes; Isabel Sola; Ander Izeta; Jose Manuel Sanchez-Morgado; Jose Manuel Gonzalez; Sara Alonso; David Escors; CM Sanchez. Interference with virus and bacteria replication by the tissue-specific expression of antibodies and interfering molecules. *Advances in Animal Virology*. pp. 389 - 401. Oxford and IBH Publishing, 1999.

Type of production: Book chapter

Format: Book

- 74** L Enjuanes; I Sola; A Izeta; JM Sanchez-Morgado; JM Gonzalez; S Alonso; D Escors; CM Sanchez. Interference with virus replication by the tissue specific expression of interfering molecules. *Mechanisms in the pathogenesis of enteric diseases 2*. pp. 31 - 45. Kluwer Academic / Plenum Publishers, 1999.

Type of production: Book chapter

Format: Book

- 75** Luis Enjuanes; Isabel Sola; Joaquin Castilla; Jose Manuel Sanchez-Morgado; Ander Izeta; Zoltan Penzes; Jose Manuel Gonzalez; Sara Alonso; David Escors; Maria Muntion; Carlos M Sanchez. Interference with virus replication by the tissue specific expression of interfering molecules. *Farm Animal Genomes. ask force on Biotechnology Research of the European Commission and USA*. European Union, 1998.

Type of production: Book chapter

Format: Book

Corresponding author: No

- 76** D Escors; G Kochan; K Breckpot; J Ginderachter; JE Talmadge. Myeloid-derived suppressor cells and cancer. *Springer Briefs in Biochemistry and Molecular Biology*. Springer, 2016.

Type of production: Scientific book or monograph

Format: Book

Corresponding author: Yes

- 77** David Escors; Karine Breckpot; Frederick Arce; Grazyna Kochan; Holly Stephenson. *Lentiviral Vectors and Gene Therapy*. Springer Briefs in Biochemistry and Molecular Biology. Springer, 22/03/2012.

Type of production: Scientific book or monograph

Format: Book

- 78** D Escors; K Breckpot; F Arce; G Kochan; H Stephenson. *Lentiviral vectors and gene therapy*. Springer Briefs in Biochemistry and Molecular Biology. Springer, 2012.

Type of production: Scientific book or monograph

Format: Book

Corresponding author: Yes

- 79** D Escors; G Kochan. Editorial on "PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis". *Translational Cancer Research*. pp. 10.21037/tcr.2018.01.01. 17/12/2017.

DOI: 10.21037/tcr.2018.01.01

Type of production: Scientific edition

Format: Journal

Position of signature: 1

Total no. authors: 2

Corresponding author: Yes

- 80** H Arasanz; M Zuazo; R Vera; G Kochan; D Escors. Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. *Lung cancer management*. In press,

Type of production: Scientific edition

Format: Journal

Corresponding author: Yes

- 81** C Hernandez; H Arasanz; L Chocarro; A Bocanegra; M Zuazo; G Fernandez-Hinojal; E Blanco; R Vera; D Escors; G Kochan. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. *Int J Mol Sci*. pp. 2411. 2020. ISSN 1422-0067
DOI: 10.3390/ijms21072411
Type of production: Review **Format:** Journal
Corresponding author: Yes
Impact source: ISI **Category:** Biochemistry
Impact index in year of publication: 4.183
Relevant publication: Yes
- 82** A Bocanegra; E Blanco; G Fernandez; H Arasanz; L Chocarro; M Zuazo; P Morente; R Vera; D Escors; G Kochan. PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. *Int J Mol Sci*. 21 - 16, pp. 5918. 2020. ISSN 1422-0067
DOI: 10.3390/ijms21165918
Type of production: Review **Format:** Journal
Impact source: ISI **Category:** Molecular Medicine
Impact index in year of publication: 4.556
- 83** L Chocarro de Erauso; M Zuazo; H Arasanz; A Bocanegra; C Hernandez; G Fernandez; MJ Garcia Granda; E Blanco; R Vera; G Kochan; D Escors. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. *Frontiers in Pharmacology*. 11, pp. 441. 2020. ISSN 16639812
DOI: 10.3389/fphar.2020.00441
Type of production: Review **Format:** Journal
Corresponding author: Yes
Impact source: ISI **Category:** Pharmacology
Impact index in year of publication: 4.4 **Journal in the top 25%:** Yes
- 84** M Zuazo; H Arasanz; A Bocanegra; L Chocarro; R Vera; D Escors; H Kagamu; G Kochan. Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapy. *EMBO Mol Med*. 12 - 9, pp. e12706. 2020. ISSN 1757-4676
DOI: 10.15252/emmm.202012706
Type of production: Review
Corresponding author: Yes
Impact source: ISI **Category:** Molecular Medicine
Impact index in year of publication: 10.293 **Journal in the top 25%:** Yes
- 85** I Dufait; E Van Valkenborgh; E Menu; D Escors; M De Ridder; K Breckpot. Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. *Oncotarget*. doi: 10.18632/oncotarget. 2016.
Type of production: Review **Format:** Journal
Position of signature: 4
Total no. authors: 6
- 86** D Escors; T Liechtenstein; N Perez Janices; J Schwarze; I Dufait; C Goyvaerts; A Lanna; F Arce; I Blanco Luquin; G Kochan; D Guerrero Setas; K Breckpot. Assessing T-cell responses in anticancer immunotherapy: dendritic cells or myeloid-derived suppressor cells?. *Oncolimmunology*. 2, pp. 26148. 2013.
Type of production: Review **Format:** Journal

- 87** T Liechtenstein; N Perez Janices; C Bricogne; A Lanna; I Dufait; C Goyvaerts; R Laranga; A Padella; F Arce; M Baratchian; N Ramirez; N Lopez; G Kochan; I Blanco Luquin; D Guerrero Setas; K Breckpot; D Escors. Immune modulation by genetic modification of dendritic cells with lentiviral vectors. *Virus Res.* 176, pp. 1. 2013.
Type of production: Review **Format:** Journal
- 88** I Dufait; T Liechtenstein; A Lanna; K Breckpot; D Escors. Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy. *Immunol Endocr Metab Agents Med Chem.* 12, pp. 224. 2012.
Type of production: Review **Format:** Journal
- 89** T Liechtenstein; I Dufait; C Bricogne; A Lanna; J Pen; K Breckpot; D Escors. PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal. *J Clin Cell Immunol.* 12, pp. 6. 2012.
Type of production: Review **Format:** Journal
- 90** H Arasanz; M Gato Cañas; M Zuazo; Maria Ibañez Veja; K Breckpot; G Kochan; D Escors. PD1 signal transduction pathways in T cells. *Oncotarget.* In press.,
Type of production: Review **Format:** Journal
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 5.168 **Journal in the top 25%:** Yes
- 91** M Zuazo; M Gato; H Arasanz; Gonzalo Fernandez Hinojal; D Escors; G Kochan. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives. *Arch Immunol Ther Exp.* 66, pp. 113 - 123. 2018.
DOI: 10.1007/s00005-017-0492-4.
Type of production: Bibliographic review **Format:** Journal
Position of signature: 5
Total no. authors: 6 **Corresponding author:** Yes
Relevant publication: Yes
- 92** H Arasanz; M Gato Cañas; M Zuazo; M Ibañez Veja; K Breckpot; G Kochan; D Escors. PD1 signal transduction pathways in T cells. *Oncotarget.* In press, 2017.
Type of production: Bibliographic review **Format:** Journal
Position of signature: 7
Total no. authors: 7 **Corresponding author:** Yes
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 5 **Journal in the top 25%:** Yes
Relevant publication: Yes
- 93** M Gato; I Blanco Luquin; M Zudaire; XM de Morentin; E Perez Valderrama; A Zabaleta; G Kochan; D Escors; J Fernandez Irigoyen; E Santamaria. Drafting the proteome landscape of myeloid-derived suppressor cells. *Proteomics.* 16, pp. 367. 2016.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
Impact source: ISI **Category:** Biochemical research methods
Impact index in year of publication: 3.807 **Journal in the top 25%:** Yes
Relevant publication: Yes
- 94** H Arasanz; M Zuazo; R Vera; G Kochan; D Escors. Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. *Lung Cancer Manag.* 7, pp. LMT07. 2018.
Type of production: Bibliographic review **Format:** Journal
Position of signature: 5

Total no. authors: 5**Corresponding author: Yes**

- 95** H Arasanz Esteba; A Lacalle; J Lecumberri; A Lascoiti; I Blanco Luquin; M Gato Cañas; L Perez Ricarte; M Zuazo; G Fernandez Hinojal; V Arteta; G Kochan; D Escors. Immunotherapy in Malignant Melanoma: Recent Approaches and New Perspectives. Melanoma Management. In press, 2017.

Type of production: Bibliographic review**Format:** Journal**Position of signature:** 12**Total no. authors:** 12

- 96** M Zuazo; M Gato Cañas; N Llorente; M Ibañez Vea; H Arasanz; G Kochan; D Escors. Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. Annals of Trans Med. In press, 2017.

Type of production: Bibliographic review**Format:** Journal**Position of signature:** 7**Total no. authors:** 7**Corresponding author: Yes**

- 97** M Zuazo; M Gato Canas; H Arasanz Esteban; G Fernandez Hinojal; M Ibañez Vea; L Chocarro; R Vera; D Escors; G Kochan. PD-L1 Signal Transduction Mechanisms in Cancer Cells. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry. 17 - 2, pp. 72 - 86. 2017.

Type of production: Bibliographic review**Format:** Journal**Position of signature:** 8**Total no. authors:** 9**Corresponding author: Yes**

- 98** M Gato; H Arasanz; I Blanco Luquin; V Arteta; G Kochan; D Escors. Novel immunotherapies for the treatment of melanoma. Immunotherapy. 8, pp. 613. 2016.

Type of production: Bibliographic review**Format:** Journal**Corresponding author:** Yes**Impact source:** ISI**Impact index in year of publication:** 2.083

- 99** I Dufail; E Van Valckenborgh; E Menu; D Escors; M De Ridder; Breckpot K. Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget. pp. doi 10.18632/oncotarget.8311. 2016.

Type of production: Bibliographic review**Format:** Journal**Impact source:** ISI**Impact index in year of publication:** 6.359**Category:** Oncology**Journal in the top 25%:** Yes

- 100** T Liechtenstein; I Blanco Luquin; M Zudaire; G Kochan; D Escors. Immunoterapia genética con células dendríticas para el tratamiento del cáncer. Anales del Sistema Sanitario de Navarra. 38, pp. 279. 2015.

Type of production: Bibliographic review**Format:** Journal**Corresponding author:** Yes**Impact source:** ISI**Impact index in year of publication:** 0.783

- 101** N Ramirez; L Beloki; M Ciaurriz; M Rodriguez Calvillo; D Escors; C Mansilla; E Bandres; E Olavarria. Impact of T cell selection methods in the success of clinical adoptive immunotherapy. Cell Mol Life Sci. 71, pp. 1211 - 1224. 2014.

Type of production: Bibliographic review**Impact source:** ISI**Impact index in year of publication:** 5.808**Category:** Molecular Biology**Journal in the top 25%:** Yes



- 102** David Guerrero Setas; Therese Liechtenstein; Noemi Perez Janices; Idoia Blanco Luquin; David Escors. Production of lentivectors for clinical use. *Immunology, endocrine and metabolic agents in medicinal chemistry*. 13, pp. 165 - 175. 2014.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
- 103** Tumour immunogenicity, antigen presentation, and immunological barriers in cancer immunotherapy. *New Journal of Science*. pii: 734515, 2014.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
- 104** David Escors Murugarren; Therese Liechtenstein; Noemi Perez Janices; Ines Dufait; J Schwarze; C Goyvaerts; Alessio Lanna; Frederick Arce; Idoia Blanco Luquin; Grazyna Kochan; David Guerrero Setas; Karine Breckpot. Assessing T cell-responses in anti-cancer immunotherapy. Dendritic cells or myeloid-derived suppressor cells?. *Oncoimmunology*. 12 - 10, pp. e26148. 2013.
Type of production: Bibliographic review
Corresponding author: Yes
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 6.283 **Journal in the top 25%:** Yes
- 105** T Liechtenstein; N Perez-Janices; C Bricogne; A Lanna; I Dufait; C Goyvaerts; R Laranga; A Padella; F Arce; M Baratchian; N Ramirez; N Lopez; G Kochan; I Blanco-Luquin; D Guerrero-Setas; K Breckpot; D Escors. Immune modulation by genetic modification of dendritic cells with lentiviral vectors. *Virus Research*. doi:pii: S0168-1702(, 2013.
Type of production: Bibliographic review
Corresponding author: Yes
Impact source: ISI
Impact index in year of publication: 2.827
- 106** Therese Liechtenstein; Noemi Perez Janices; David Escors Murugarren. Lentiviral vectors for cancer immunotherapy and clinical applications. *Cancers*. 5, pp. 815 - 837. 2013.
Type of production: Bibliographic review
Corresponding author: Yes
- 107** Grazyna Kochan; David Escors Murugarren; Karine Breckpot; David Guerrero Setas. Role of non-classical MHC class I molecules in cáncer immunosuppression. *Oncoimmunology*. 2, pp. e26491. 2013.
Type of production: Bibliographic review
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 6.283 **Journal in the top 25%:** Yes
- 108** Therese Liechtenstein; Ines Dufait; Christopher Bricogne; Alessio Lanna; Joeri Pen; Karine Breckpot; David Escors. Commentary: PD-L1/PD-1 co-stimulation, a brake for T cell activation and a T cell differentiation signal. *Journal of Clinical & Cellular Immunology*. S 12 - 2, OMICS Publishing Clinical Group, 01/12/2012.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
- 109** Therese Liechtenstein; Ines Dufait; Alessio Lanna; Karine Breckpot; David Escors. Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy. *Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry*. 12, pp. 224 - 235. Bentham Science Publishers, 01/09/2012.
Type of production: Bibliographic review **Format:** Journal



Corresponding author: Yes

- 110** Ines Dufait; Therese Liechtenstein; Alessio Lanna; Christopher Bricogne; Roberta Laranga; Antonella Padella; Karine Breckpot; David Escors. Retroviral and lentiviral vectors for the induction of immunological tolerance. Scientifica. Dx.doi.org/10.6064/2, Scientifica, 22/08/2012.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
- 111** Katarzyna Karwacz; Frederick Arce; Christopher Bricogne; Grazyna Kochan; David Escors. PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumour immunotherapy. Oncoimmunology. 1 - 1, pp. 86 - 88. Landes Bioscience, 01/01/2012.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
Impact source: ISI **Category:** Oncology
Impact index in year of publication: 6.283 **Journal in the top 25%:** Yes
- 112** Frederick Arce; Grazyna Kochan; Karine Breckpot; Holly Stephenson; David Escors. Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. Anti-cancer agents in medicinal chemistry. 12 - 1, pp. 29. Bentham Science, 01/01/2012.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
- 113** David Escors; Christopher Bricogne; Frederick Arce; Grazyna Kochan; Katarzyna Karwacz. On the mechanism of TCR down-modulation and its physiological significance. The journal of bioscience and medicine. 1 - 1, Wellcome Trust Public Access, 01/12/2011.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
- 114** Frederick Arce; Karine Breckpot; Mary Collins; David Escors. Targeting Lentiviral vectors for cancer immunotherapy. Current cancer therapy reviews. 7 - 4, pp. 248. Wellcome Trust Public Access, 01/11/2011.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
- 115** David Escors; Karine Breckpot. Lentiviral vectors in gene therapy: their current status and future potential. Archivum immunologiae et therapiarum experimentalis. 58 - 2, pp. 107 - 119. Springer, 01/04/2010.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
Impact source: ISI
Impact index in year of publication: 2.385
- 116** Karine Breckpot; David Escors. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocrine, metabolic & immune disorders drug targets. 9 - 4, pp. 328. Wellcome Trust Public Access, 01/12/2009.
Type of production: Bibliographic review **Format:** Journal
Corresponding author: Yes
- 117** Luis Enjuanes; Isabel Sola; Fernando Almazan; Javier Ortego; Ander Izeta; Jose M Gonzalez; Sara Alonso; Jose M Sanchez; David Escors; Enrique Calvo; Cristina Riquelme; Carlos Sanchez. Coronavirus derived expression systems. Journal of Biotechnology. 88 - 3, pp. 183 - 204. Elsevier, 12/07/2001.
Type of production: Bibliographic review **Format:** Journal
Impact source: ISI



Impact index in year of publication: 2.748

Works submitted to national or international conferences

- 1** **Title of the work:** A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI.
Name of the conference: ESMO
Corresponding author: Yes
City of event: Barcelona, Catalonia, Spain
Date of event: 2019
Organising entity: European Society of Medical Oncology
H Arasanz; M Zuazo; M Martinez; B Hernandez; G Fernandez; A Bocanegra; I Morilla; M Gato; L Teijeira; P Sala; MJ Garcia Granda; G Kochan; R Vera; D Escors.
- 2** **Title of the work:** Adaption of pancreatic cancer cells to AKT1 inhibition induces the acquisition of cancer stem-cell like phenotype through upregulation of mitochondrial functions.
Name of the conference: ESMO
City of event: Barcelona, Catalonia, Spain
Date of event: 2019
Organising entity: European Societe of Medical Oncology
H Arasanz; M Zuazo; A Bocanegra; M Gato; G Fernandez; C Hernandez; J Fernandez; E Santamaria; C Rodriguez; G Kochan; R Vera; D Escors.
- 3** **Title of the work:** Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Name of the conference: Congress of the Spanish Society of Immunology.
City of event: Seville, Andalusia, Spain
Date of event: 2019
Organising entity: Spanish society of Immunology
D Escors; M Zuazo; H Arasanz; G Fernandez; MJ Garcia; M Gato; A Bocanegra; M Martinez; R Vera; G Kochan.
- 4** **Title of the work:** Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
Name of the conference: ESMO
City of event: Barcelona, Catalonia, Spain
Date of event: 2019
Organising entity: European Society for Medical Oncology
M Zuazo; H Arasanz; MJ Garcia; A Bocanegra; G Fernandez; M Gato; M Martinez; B Hernandez; L Teijeira; I Morilla; R Vera; G Kochan; D Escors.
- 5** **Title of the work:** Invited lecture: Señalización de PD-L1. Implicaciones en autoinmunidad
Name of the conference: Congress of the Spanish Society for Immunology
City of event: Seville, Spain
Date of event: 2019
Organising entity: SOCIEDAD ESPAÑOLA DE INMUNOLOGIA
- 6** **Title of the work:** Overcoming intrinsic resistance to PD1/PD-L1 monotherapies in NSCLC patients by anti-PD1 and anti-LAG3 dual blockade
Name of the conference: Congress of the Spanish Society of Immunology



City of event: Seville, Andalusia, Spain

Date of event: 2019

Organising entity: Spanish Society of Immunology

MJ Garcia Granda; M Zuazo; H Arasanz; G Kochan; D Escors.

- 7** **Title of the work:** PD-L1 expression in systemic immune cell populations as potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer.

Name of the conference: Congress of the Spanish Society of Immunology

City of event: Seville, Andalusia, Spain

Date of event: 2019

Organising entity: Spanish Society of Immunology

A Bocanegra; G Fernandez; M Zuazo; H Arasanz; MJ Garcia Granda; C Hernandez; M Martinez; MJ Lecumberri; L Teijeira; R Vera; D Escors; G Kochan.

- 8** **Title of the work:** PD-L1 signaling and implications for immunotherapy, Invited lecture

Name of the conference: Conference of the Spanish Melanoma Group

Corresponding author: Yes

City of event: Bilbao, Spain

Date of event: 2019

Organising entity: Spanish Melanoma Group

- 9** **Title of the work:** Reprogramación metabólica con potenciación de la función mitocondrial como adaptación y escape a la inhibición sostenida de AKT1 en adenocarcinoma de páncreas.

Name of the conference: SEOM

Corresponding author: Yes

City of event: Pamplona, Foral Community of Navarre, Spain

Date of event: 2019

Organising entity: Spanish Society for Medical Oncology

H Arasanz; M Zuazo; A Bocanegra; E Santamaria; J Fernandez; G Fernandez; E Santamaria; M Rodriguez; R Vera; G Kochan; D Escors.

- 10** **Title of the work:** Role of complement C5a on lung cancer-associated myeloid-derived suppressor cells

Name of the conference: European Meeting on Complement in Human Disease

City of event: Madrid, Community of Madrid, Spain

Date of event: 2019

S Ortiz-Espinosa; X Morales; C Sainz; Y Senent; L Montuenga; G Kochan; D Escors; C Ortiz-de-Solorzano1; D Ajona; R Pio.

- 11** **Title of the work:** Circulating CD4 senescent T cells stratify clinical responses to PD-L1/PD-1 immune checkpoint inhibitors in NSCLC

Name of the conference: European Congress of Immunology

Corresponding author: Yes

City of event: Amsterdam, Holland

Date of event: 2018

Organising entity: European Society of Immunology

M Zuazo; H Arasanz; M Gato; G Fernandez; R Vera; G Kochan; D Escors.

- 12** **Title of the work:** El silenciamiento específico de cada isoforma de AKT tiene un efecto diferencial en proliferación, apoptosis y sensibilidad a quimioterapia en adenocarcinoma de páncreas

Name of the conference: ESMO congress

Corresponding author: Yes

City of event: Madrid, Community of Madrid, Spain

Date of event: 2018

Organising entity: European Society of Medical Oncology

H Arasanz; M Zuazo; M Gato Cañas; J Fernandez Irigoyen; M Ibañez Veja; G Fernandez Hinojal; E Santamaria; G Kochan; R Vera; D Escors.

13 Title of the work: Invited lecture. "Curing cancer: PDL1-PD1 interactions"

Name of the conference: XXXI Congreso Nacional de la Asociación Española de Técnicos de Laboratorio, AETEL

City of event: Pamplona, Foral Community of Navarre, Spain

Date of event: 2018

Organising entity: AETEL

Type of entity: Foundation

D Escors.

14 Title of the work: Molecular recalibration of PD-1+ antigen-specific T cells as immunotherapy for Hepatocellular carcinoma

Name of the conference: European Congress of Immunology

City of event: Amsterdam, Holland

Date of event: 2018

Organising entity: European Society of Immunology

I Otano; D Escors; et al; M Maini.

15 Title of the work: Pre-treatment CD4 highly differentiated T cells accurately predicts clinical outcome to PD-L1/PD-1 immune checkpoint blockade in non-small cell lung carcinoma.

Name of the conference: ESMO

Corresponding author: Yes

City of event: Munich, Germany

Date of event: 2018

Organising entity: European Society of Medical Oncology

M Zuazo; H Arasanz; M Gato-Cañas; G Fernández-Hinojal; B Hernández-Marín; M Martínez-Aguillo; M Ibañez-Veja; MJ Lecumberri-Biurrun; A Fernández de Lascoiti; R Vera; G Kochan; D Escors.

16 Title of the work: Señalización de PD-L1 en células cancerosas

Name of the conference: Invited lecture. CIBA.

Corresponding author: Yes

City of event: Zaragoza, Aragon, Spain

Date of event: 2018

Organising entity: Instituto de Investigación Sanitaria de Aragón

17 Title of the work: Isoform-specific functions in pancreatic adenocarcinoma

Name of the conference: European Society of Medical Oncology, ESMO

City of event: Madrid, Community of Madrid, Spain

Date of event: 08/09/2017

Organising entity: ESMO

Type of entity: Foundation

H Arasanz; M Gato Cañas; M Zuazo Ibarra; M Ibañez Veja; G Fernández; J Fernandez; E Santamaria; R Vera; G Kochan; D Escors.

18 Title of the work: Molecular recalibration of PD1+ antigen-specific T cells from blood and liver

Name of the conference: 2017 International HBV meeting

City of event: Washington, United States of America

Date of event: 03/09/2017



I Otano; A Schurich; H Singh; F Robertson; B Davidson; G Fusai; F Arce; J Hansi; P Kennedy; A Bertolotti; S Xue; H Stauss; D Escors; M Mala.

19 Title of the work: Aspectos básicos de la inmunoterapia

Name of the conference: Jornada de actualización en inmunoterapia dirigida a fármacos

Corresponding author: Yes

City of event: Pamplona, Foral Community of Navarre, Spain

Date of event: 07/06/2017

Organising entity: Roche

Type of entity: Business

D Escors.

20 Title of the work: PD1 engagement causes T cell receptor downmodulation in activated T cells.

Name of the conference: 40 Spanish National Congress of Immunology

Corresponding author: Yes

City of event: Zaragoza, Aragon, Spain

Date of event: 25/05/2017

Organising entity: SOCIEDAD ESPAÑOLA DE INMUNOLOGIA

D Escors; M Gato Cañas; M Zuazo Ibarra; H Arasanz Esteban; M Ibañez Vea; G Kochan.

21 Title of the work: Function of Granzyme B in myeloid-derived suppressor cells.

Name of the conference: BACR

City of event: Leuven, Belgium

Date of event: 2017

I Dufait; D Escors; M De Ridder; K Breckpot.

22 Title of the work: DL1/PD1 Expression As A Biomarker? A Holistic View On PDL1-PD1 Interactions

Name of the conference: Invited Speaker. Immune Checkpoint Inhibitors Europe 2016

City of event: Munich, Germany

Date of event: 2016

Organising entity: Hanson Wade

D Escors.

23 Title of the work: Diferenciación ex vivo de MDSCs que modelan el ambiente tumoral y sus aplicaciones para evaluar tratamientos mediante técnicas de monitorización celular a tiempo real

Name of the conference: Invited lecture

Corresponding author: Yes

City of event: San Sebastián, Foral Community of Navarre, Spain

Date of event: 2016

Organising entity: Izasa, S.A.

Type of entity: Business

D Escors.

24 Title of the work: Functional consequences of interfering with the PDL1-PD1 interaction

Name of the conference: Invited lecture

Corresponding author: Yes

City of event: San Sebastian, Basque Country, Spain

Date of event: 2016

Organising entity: Merck Sharp & Dohme España, S.A. **Type of entity:** Business



- 25 Title of the work:** Genetic immunotherapies for the treatment of melanoma that inhibit MDSC differentiation and function
Name of the conference: Spanish National Congress of Immunology
Corresponding author: Yes
City of event: Alicante, Valencian Community, Spain
Date of event: 2016
Organising entity: SOCIEDAD ESPAÑOLA DE INMUNOLOGIA
 M Gato Cañas; I Blanco Luquin; H Arasanz; V Arteta Sanchez; M Barrado; M Zuazo; J Fernandez Irigoyen; E Santamaría; G Kochan; D Escors.
- 26 Title of the work:** Genetically engineering HBV-specific CD8+ T cells resistant to TRAIL-mediated apoptosis
Name of the conference: The International Liver Congress
City of event: Barcelona, Catalonia, Spain
Date of event: 2016
 I Otano; F Arce; S Singh; A Schurich; D Peppas; R Gilson; G Fusai; H Stauss; D Escors; M Maini.
- 27 Title of the work:** Granzyme B expression in myeloid-derived suppressor cells: a current unidentified mechanism?
Name of the conference: European Macrophage and dendritic cell society
City of event: Amsterdam, Holland
Date of event: 2016
 I Dufait; et al; K Breckpot.
- 28 Title of the work:** Granzyme B expression in myeloid-derived suppressor cells: a current unidentified mechanism?
Name of the conference: International Society of Cancer Metabolism
City of event: Ghent, Belgium
Date of event: 2016
 I Dufait; et al; K Breckpot.
- 29 Title of the work:** Granzyme B expression in myeloid-derived suppressor cells: a current unidentified mechanism?
Name of the conference: VIB Cell symposium-Hallmarks of cancer
City of event: Brussels, Belgium
Date of event: 2016
 I Dufait; et al; K Breckpot.
- 30 Title of the work:** Granzyme B expression in myeloid-derived suppressor cells: a current unidentified mechanism?
Name of the conference: VUB PhD day
City of event: Brussels, Belgium
Date of event: 2016
 I Dufait; et al; K Breckpot.
- 31 Title of the work:** Inmunología y cáncer
Name of the conference: Invited Speaker. Curso Manejo de efectos adversos inmuno-relacionados. De la teoría a la práctica
City of event: Pamplona, Foral Community of Navarre, Spain
Date of event: 2016
End date: 2016
Organising entity: Hospital de Navarra. Bristol-Meyers



D Escors.

- 32** **Title of the work:** Molecular mechanisms of PD1-dependent T cell suppression
Name of the conference: Invited Speaker. II reunión traslacional en melanoma
City of event: Barcelona, Catalonia, Spain
Date of event: 2016
Organising entity: Grupo Español de Melanoma
- 33** **Title of the work:** Ex vivo generation of MDSC that model the tumor suppressive environment in colorectal cancer
Name of the conference: PhD day, VUB
City of event: Brussels, Belgium
Date of event: 2015
I Dufait; et al; K Breckpot.
- 34** **Title of the work:** Ex vivo-generated MDSC as a suitable model for in vivo tumour-infiltrating MDSC in colorectal cancer
Name of the conference: Annual BACR meeting
City of event: Brussels, Belgium
Date of event: 2015
Organising entity: Vrije Universiteit Brussel
I Dufait; JK Schwarze; T Liechtenstein; L Wim; VN Verovski; D Escors; M De Ridder; K Breckpot.
- 35** **Title of the work:** Ex vivo-generated MDSC as a suitable model for in vivo tumour-infiltrating MDSC in colorectal cancer
Name of the conference: Belgian association for cancer research
City of event: Brussels, Belgium
Date of event: 2015
I Dufait; et al; K Breckpot.
- 36** **Title of the work:** Genetically engineering HBV-specific CD8+ T cells resistant to TRAIL-mediated apopto-sis
Name of the conference: IV European Congress of Immunology
City of event: Viena, Austria
Date of event: 2015
Organising entity: Sociedad Europea de Inmunologia
I Otano; F Arce; H Singh; A Schurich; D Peppia; R Gilson; G Fussai; H Stauss; D Escors; M Maini.
- 37** **Title of the work:** highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets using proteomics
Name of the conference: IV Congress of junior researchers in proteomics
Corresponding author: Yes
City of event: Bilbao,
Date of event: 2015
Organising entity: Sociedad Española de Proteómica
City organizing entity: Bilbao, Basque Country, Spain
M Gato; J Fernandez; I Blanco; T Liechtenstein; D Guerrero Setas; D Escors; G Kochan; E Santamaria.
- 38** **Title of the work:** A clinical-grade constitutive packaging cell line for the production of self-inactivating lentiviral vectors
Name of the conference: ESGCT and NVGCT Collaborative Congress



City of event: La Haya, Holland

Date of event: 2014

Organising entity: European Society of Gene and Cell Therapy
S Knight; K Sanber; S Stephen; S Ferraresso; R Baley; D Escors; G Santilli.

39 Title of the work: A highly efficient MDSC differentiation system that overcomes tumour establishment

Name of the conference: Hason Wade Tumour model conference

Corresponding author: Yes

City of event: London, United Kingdom

Date of event: 2014

Organising entity: Hason Wade

M Gato; T Liechtenstein; I Blanco Luquin; MI Zudaire; D Guerrero; G Kochan; D Escors.

40 Title of the work: Differentiation of myeloid-derived suppressor cells from bone marrow using colorectal cancer cell-conditioned media

Name of the conference: Belgian association for cancer research

City of event: Ghent, Belgium

Date of event: 2014

I Dufait; et al; K Breckpot.

41 Title of the work: Differentiation of myeloid-derived suppressor cells from bone marrow using conditioned media from LV-modified colorectal cancer cells.

Name of the conference: Lentiviral vectors: concepts, practice, hope and future

City of event: Brussels, Belgium

Date of event: 2014

I Dufait; et al; K Breckpot.

42 Title of the work: Differentiation of myeloid-derived suppressor cells from bone marrow using conditioned media from LV-modified colorectal cancer cells.

Name of the conference: VUB PhD Day

City of event: Brussels, Belgium

Date of event: 2014

I Dufait; et al; K Breckpot.

43 Title of the work: Interference with PD-L1/PD-1 co-stimulation results in effective anti-tumour immunity by preventing ligand-induced T cell receptor down-modulation in effector CD8 T cells.

Name of the conference: Symposium: Lentiviral vectors: concepts, practise, hope and future

Corresponding author: Yes

City of event: Bruselas, Belgium

Date of event: 2014

Organising entity: Vrije Universiteit Brussels

D Escors; T Liechtenstein; N Perez Janices; A Lanna; C Bricogne; K Karwacz; D Guerrero Setas; K Breckpot.

44 Title of the work: Lentivirus-mediated generation of stimulatory or tolerogenic dendritic cells

Name of the conference: Symposium on Lentiviral vectors: concepts, practise, hope and future

Corresponding author: Yes

City of event: Brussels, Belgium

Date of event: 2014

Organising entity: Vrije Universiteit Brussels

D Escors.



- 45** **Title of the work:** Therapeutic application of selective ERK activation for the treatment of inflammatory arthritis
Name of the conference: Symposium: Lentiviral vectors: concepts, practise, hope and future
Corresponding author: Yes
City of event: Bruselas, Spain
Date of event: 2014
Organising entity: Vrije Universiteit Brussels
F Arce; K Breckpot; H Stephenson; K Karwacz; MR Ehrenstein; M Collins; D Escors.
- 46** **Title of the work:** Use of ex vivo tumour-specific MDSCs in cancer therapy
Name of the conference: Routing cancer immunology and immunotherapy
Corresponding author: Yes
City of event: Pamplona, Foral Community of Navarre, Spain
Date of event: 2014
Organising entity: Universidad de Navarra
- 47** **Title of the work:** A clinical-grade constitutive packaging cell line for the production of self-inactivating lentiviral vectors
Name of the conference: British Society for Gene and Cell Therapy (BSGCT)
City of event: London, United Kingdom
Date of event: 2013
End date: 2013
Organising entity: BSGT
Sean Knight; K Sanber; Sam Stephen; Ranbir Bailey; David Escors Murugarren; G Santilli; Adrian Thrasher; Mary Collins; Yasu Takeuchi.
- 48** **Title of the work:** Ex vivo differentiation of myeloid-derived suppressor cells
Name of the conference: Invited lecture
Corresponding author: Yes
City of event: Oxford, United Kingdom
Date of event: 2013
Organising entity: Universidad de Oxford
D Escors.
- 49** **Title of the work:** Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells
Name of the conference: ESGCT
City of event: Madrid, Community of Madrid, Spain
Date of event: 2013
Organising entity: European Society of Gene and Cell Therapy
K Breckpot; J Pen; B De Keersmaecker; C Heriman; J Corthals; T Liechtenstein; D Escors; K Thielemans.
- 50** **Title of the work:** Interference with PDL1-PD1 co-stimulation results in effective anti-tumour immunity by preventing ligand-induced T cell receptor down-modulation in effector CD8 T cells
Name of the conference: ESGCT
Corresponding author: Yes
City of event: Madrid, Community of Madrid, Spain
Date of event: 2013
Organising entity: European Society for Gene and Cell Therapy



D Escors; T Liechtenstein; N Perez Janices; A Lanna; C Bricogne; K Karwacz; D Guerrero Setas; K Breckpot.

51 Title of the work: Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy

Name of the conference: ESGCT congress

City of event: Madrid, Spain

Date of event: 2013

End date: 2013

Organising entity: ESGCT

Therese Liechtenstein; Noemi Perez Janices; Karine Breckpot; David Escors Murugarren.

52 Title of the work: Molecular tuning of telomerase activity in highly differentiated human primary CD28-CD27- T cells

Name of the conference: 15th International Congress of Immunology

City of event: Milan, Italy

Date of event: 2013

End date: 2013

Alessio Lanna; Sian Henson; David Escors Murugarren; Arne Akbar.

53 Title of the work: Targeting the p38-MK2 pathway to enhance Th1 polarisation by myeloid DC for therapeutic cancer vaccination

Name of the conference: TWELFTH INTERNATIONAL CONFERENCE ON PROGRESS IN VACCINATION AGAINST CANCER

City of event: Nottingham, United Kingdom

Date of event: 11/09/2012

End date: 13/09/2012

Organising entity: EFIS – European Federation of Immunological Societies

HA Franks; Q Wang; SJ Foan; Mary K Collins; David Escors; PM Patel; AM Jackson.

54 Title of the work: Selective ERK activation in dendritic cells for the treatment of arthritis

Name of the conference: EUROSCICON 2012

City of event: Londres, Inner London, United Kingdom

Date of event: 07/2012

End date: 07/2012

Organising entity: European Science Congresses

David Escors.

55 Title of the work: PD-L1/PD-1 co-stimulation contributes to ligand-induced T cell receptor down-modulation, a mechanism that prevents T cell hyperactivation

Name of the conference: International Congress on Autoimmunity, Autoimmunity 2012

City of event: Granada, Spain

Date of event: 09/05/2012

End date: 13/05/2012

Organising entity: Autoimmunity network

Katarzyna Karwacz; Grazyna Kochan; Frederick Arce; David Escors.

56 Title of the work: Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells and suppresses experimental inflammatory arthritis

Name of the conference: EULAR

City of event: Londres, Inner London, United Kingdom

Date of event: 05/2011



End date: 05/2011

Organising entity: European League Against Arthritis

David Escors.

57 Title of the work: Influence of differential dendritic cell maturation on Treg suppression

Name of the conference: VEB Brussels

City of event: Bruselas, Belgium

Date of event: 2011

End date: 2011

Organising entity: Universidad libre de Bruselas

Type of entity: University

City organizing entity: Bruselas, Belgium

J Pen; B De Keersmaecker; C Heirman; J Corthals; D Escors; A Bonehill; K Thielemans; K Breckpot; J Aerts.

58 Title of the work: Lentiviral vectors encoding influenza A nucleoprotein and vFLIP induce potent CD8 T-cell responses and confer protection against lethal flu challenge

Name of the conference: BSGT

City of event: Londres, Inner London, United Kingdom

Date of event: 2010

End date: 2010

Organising entity: British society of gene therapy

Douglas MacDonald; M Whelan; David Escors; WMC Rosenberg; Mary K Collins. "Lentiviral vectors encoding influenza A nucleoprotein and vFLIP induce potent CD8 T-cell responses and confer protection against lethal flu challenge. Human Gene Ther. 21:500-500".

59 Title of the work: Lentiviral vectors for TCR gene transfer: Improved Function of TCR-transduced T cells after non-activating cytokine-mediated transduction

Name of the conference: BSGT

City of event: Londres, Inner London, United Kingdom

Date of event: 2010

End date: 2010

Organising entity: British society of gene therapy

M Perro; J Tsang; SA Xue; D Escors; M Cesco-Gaspere; D Pospori; L Gao; D Hart; M Collins; H Stauss; EC Morris. "Lentiviral vectors for TCR gene transfer: Improved Function of TCR-transduced T cells after non-activating cytokine-mediated transduction. Human Gene Ther. 21:512-512".

60 Title of the work: Targeted activation of ERK pathway with lentiviral vectors to induce antigen-specific peripheral tolerance

Name of the conference: BSGT

City of event: Londres, Inner London, United Kingdom

Date of event: 2010

End date: 2010

Organising entity: British society of Gene therapy

F Arce; K Breckpot; M Ehrenstein; MK Collins; D Escors. "Targeted activation of ERK pathway with lentiviral vectors to induce antigen-specific peripheral tolerance. Human Gene Ther. 21:499-500".

61 Title of the work: The immunogenicity of HIV 1-derived lentiviral vectors is mediated by TLR3 and TLR7

Name of the conference: Inflammation 2010

City of event: Luxemburgo, Luxembourg (Grand-Duché), Luxembourg

Date of event: 2010

End date: 2010

Organising entity: RSL



K Breckpot; D Escors; L Lopes; S Van Lint; M Collins.

- 62 Title of the work:** Therapeutic application of selective ERK activation for the treatment of inflammatory arthritis
Name of the conference: XVIII Annual Congress of the European Society of Gene and Cell Therapy
City of event: Milan, Italy
Date of event: 2010
End date: 2010
Organising entity: European Society of Gene and Cell Therapy
Frederick Arce; Karine Breckpot; Holly Stephenson; Katarzyna Karwacz; Michael R Ehrenstein; Mary Collins; David Escors. "Therapeutic application of selective ERK activation for the treatment of inflammatory arthritis. Human Gene Ther. 21:1445-1446".
- 63 Title of the work:** Investigation of the requirement for skin DC in the activation of lentiviral vaccination reponses
Name of the conference: BSI
City of event: Glasgow, United Kingdom
Date of event: 2009
End date: 2009
Organising entity: British society of immunology
H Goold; D Escors; R Chakraverty; CL Bennett.
- 64 Title of the work:** Non-Integrating Lentiviral Vectors for Vaccination.
Name of the conference: 12th Annual Meeting of the American Society of Gene Therapy.
City of event: San Diego, United States of America
Date of event: 2009
Organising entity: American society of Gene Therapy
K Karwacz; D Escors; A Thrasher; M Collins.
- 65 Title of the work:** Investigation of the requirement for skin dendritic cells in the activation of lentiviral vaccination responses
Name of the conference: BSI
City of event: United Kingdom
Date of event: 2008
End date: 2008
Organising entity: British society of immunology
H Goold; D Escors; R Chakraverty; CL Bennett. "Investigation of the requirement for skin DC in the activation of lentiviral vaccination reponses. Immunology. 125:53-53".
- 66 Title of the work:** Sustained antigen presentation after lentiviral immunization
Name of the conference: 16th Annual Congress of the European Society of Gene and Cell Therapy
City of event: Brugge, Belgium
Date of event: 2008
End date: 2008
Organising entity: European Society of Gene and Cell Therapy
F Arce; H Rowe; L Lopes; D Escors; B Chain; MK Collins. "Sustained antigen presentation after Lentiviral immunization. Human Gene Ther. 19:1141-1142".
- 67 Title of the work:** Modulation of the immune response by lentivector targeting of intracellular pathways
Name of the conference: European Society of Gene and Cell Therapy (ESGC) Congress
City of event: Rotterdam, Holland



Date of event: 2007

End date: 2007

Organising entity: European Society of Gene and Cell Therapy (ESGC).

D Escors; L Lopes; M Collins. "Modulation of the immune response by lentivector targeting of intracellular pathways. Human Gene Ther. 18:955-993".

68 Title of the work: Non-integrating lentiviral vectors for immunization

Name of the conference: European Society of Gene and Cell Therapy (ESGC) Congress

City of event: Rotterdam, Holland

Date of event: 2007

End date: 2007

Organising entity: European Society of Gene and Cell Therapy (ESGC)

K Karwacz; L Apolonia; D Escors; L Lopes; M Collins. "Non-integrating lentiviral vectors for immunization. Human Gene Ther. 18:994-1092".

69 Title of the work: Characterization of phosphorylation in transmissible gastroenteritis coronavirus nucleocapsid protein in infected cells by two-dimensional nano-liquid chromatography coupled to ion-trap mass spectrometry

Name of the conference: I Congress of the Spanish Proteomics Society

City of event: Cordoba, Spain

Date of event: 2005

End date: 2005

Organising entity: SOCIEDAD ESPAÑOLA DE PROTEOMICA

E Calvo; D Escors; JA Lopez; JM Gonzalez; A Alvarez; E Arza; L Enjuanes.

70 Title of the work: Influence of coronavirus nucleoprotein phosphorylation in virus replication

Name of the conference: International Virology Congress

City of event: San Francisco, United States of America

Date of event: 2005

End date: 2005

F Almazan; E Calvo; D Escors; C Galan; E Alvarez; ML De Diego; C Capiscol; J Reguera; L Enjuanes.

71 Title of the work: Characterization of phosphorylation state and organelle association during infection in the TGEV nucleoprotein by two-dimensional liquid chromatography coupled to ion-trap mass spectrometry

Name of the conference: II European Congress of Virology

City of event: Madrid, Community of Madrid, Spain

Date of event: 2004

End date: 2004

Organising entity: Eurovirology

E Calvo; JA Lopez; E Camafeita; S Alonso; D Escors; L Enjuanes.

72 Title of the work: Coronavirus reverse genetics and vaccine development

Name of the conference: International Conference on SARS, one year after the (first) outbreak

City of event: Lübeck, Germany

Date of event: 2004

End date: 2004

L Enjuanes; F Almazan; I Sola; J Ortego; S Zuniga; S Alonso; D Escors; C Galan; JL Moreno; C Capiscol; ML De Diego.



- 73** **Title of the work:** Coronavirus reverse genetics and vector development
Name of the conference: Eurovirology
City of event: Madrid, Community of Madrid, Spain
Date of event: 2004
End date: 2004
Organising entity: Eurovirology
L Enjuanes; I Sola; S Zuniga; F Almazan; J Ortego; JL Moreno; D Escors.
- 74** **Title of the work:** Coronavirus reverse genetics and vector development
Name of the conference: IV jornada de virologia
City of event: Barcelona, Catalonia, Spain
Date of event: 2004
End date: 2004
Organising entity: Seccio de virologia de la Societat Catalana de Biologia
L Enjuanes; F Almazan; I Sola; J Ortego; D Escors; S Zuniga.
- 75** **Title of the work:** Localización de la señal de encapsidación (Psi) del coronavirus de la gastroenteritis porcina transmissible (TGEV)
Name of the conference: VIII Spanish National Congress of Virology
City of event: Barcelona, Catalonia, Spain
Date of event: 2003
End date: 2003
Organising entity: Spanish Society of Virology
C Capiscol; D Escors; L Enjuanes.
- 76** **Title of the work:** Location of the Transmissible Gastroenteritis Coronavirus packaging signal (Psi)
Name of the conference: IX International Symposium on Nidovirus (Arterivirus and Coronavirus)
City of event: Paris, Île de France, France
Date of event: 2003
End date: 2003
Organising entity: IX International Symposium on Nidovirus (Arterivirus and Coronavirus)
D Escors; C Capiscol; L Enjuanes.
- 77** **Title of the work:** Coronavirus reverse genetics: viral based vectors for gene expression.
Name of the conference: Viral based vectors
City of event: Madrid, Community of Madrid, Spain
Date of event: 2002
End date: 2002
Organising entity: Juan March Institute
L Enjuanes; F Almazan; I Sola; J Ortego; S Alonso; D Escors; S Zuniga.
- 78** **Title of the work:** Localization of the transmissible gastroenteritis coronavirus (TGEV) encapsidation signal
Name of the conference: International Congress of Virology (IUMS Congress)
City of event: Paris, Île de France, France
Date of event: 2002
End date: 2002
Organising entity: International Society of Virology
D Escors; J Ortego; L Enjuanes.



- 79** **Title of the work:** Nature of the virus associated to the endemic balkan nephropathy. Endemic Balkan Nephropathy (BEN) programme.
City of event: Belgrado, Serbia
Date of event: 2002
End date: 2002
C Riquelme; D Escors; J Ortego; C Sanchez; B Uzelac-Keserovic; L Enjuanes.
- 80** **Title of the work:** Complementation of defective transmissible gastroenteritis virus by packaging cell lines.
Name of the conference: Comparison of the Mechanisms of Cellular Vesicle and Viral Membrane Fusion
City of event: Madrid, Community of Madrid, Spain
Date of event: 2001
End date: 2001
Organising entity: Juan March Institute for Studies and Investigations
J Ortego; D Escors; L Enjuanes.
- 81** **Title of the work:** Development of biosafe viral vectors based on defective coronavirus genomes
Name of the conference: VII Spanish National Congress of Virology
City of event: Valencia, Valencian Community, Spain
Date of event: 2001
End date: 2001
Organising entity: SOCIEDAD ESPAÑOLA DE VIROLOGIA
J Ortego; I Sola; D Escors; L Enjuanes.
- 82** **Title of the work:** Development of safe vectors based on propagation defective coronavirus genomes
Name of the conference: X European Congress of Biotechnology. Biotechnological challenges in the new milenium
City of event: Madrid, Community of Madrid, Spain
Date of event: 2001
End date: 2001
Organising entity: European Society of Biotechnology
J Ortego; I Sola; D Escors; J Plana-Duran; L Enjuanes.
- 83** **Title of the work:** Structure and composition of the transmissible gastroenteritis virus. VII Spanish National Congress of Virology
Name of the conference: VII Spanish National Congress of Virology
City of event: Valencia, Valencian Community, Spain
Date of event: 2001
End date: 2001
Organising entity: SOCIEDAD ESPAÑOLA DE VIROLOGIA
D Escors; E Camafeita; J Ortego; L Enjuanes.
- 84** **Title of the work:** The membrane (M) protein of transmissible gastroenteritis coronavirus adopts two topologies in the viral envelope
Name of the conference: VI International Symposium of plus-stranded RNA viruses
City of event: Pais, Île de France, France
Date of event: 2001
End date: 2001
Organising entity: International society of virology
D Escors; E Camafeita; H Laude; J Ortego; L Enjuanes.



- 85** **Title of the work:** Developing safe vectors based on trans-complementation of defective TGEV by packaging cell lines.
Name of the conference: European International Congress (European Virology 2000)
City of event: Glasgow, United Kingdom
Date of event: 2000
End date: 2000
Organising entity: European society of virology
J Ortego; D Escors; H Laude; L Enjuanes.
- 86** **Title of the work:** Interaction of the TGEV membrane protein with the internal core. Structural effects.
Name of the conference: European International Congress (European Virology 2000)
City of event: Glasgow, United Kingdom
Date of event: 2000
End date: 2000
Organising entity: European society of Virology
J Ortego; D Escors; L Enjuanes.
- 87** **Title of the work:** Structure and composition of the TGEV core.
Name of the conference: VIII International Symposium for Nidovirus (Coronavirus y Arterivirus)
City of event: Pennsylvania, United States of America
Date of event: 2000
End date: 2000
Organising entity: University of Pennsylvania
D Escors; J Ortego; L Enjuanes.
- 88** **Title of the work:** Tissues specific expression by using vectors based on coronavirus genomes and transgenic animals
Name of the conference: OECD Workshop. Molecular farming
City of event: La Frande Motte, France
Date of event: 2000
End date: 2000
Organising entity: OECD
L Enjuanes; I Sola; F Almazan; A Izeta; JM Gonzalez; S Alonso; JM Sanchez-Morgado; E Calvo; J Ortego; D Escors; C Riquelme; P Barrado; C Sanchez; J Plana-Duran; M Balasch.
- 89** **Title of the work:** Composition of transmissible gastroenteritis coronavirus core.
Name of the conference: VI Spanish National Congress of Virology. Spanish Society of Microbiology
City of event: Majadahonda, Community of Madrid, Spain
Date of event: 1999
End date: 1999
Organising entity: Institute for Health Carlos III
D Escors; D Gonzalez; J Ortego; L Enjuanes.
- 90** **Title of the work:** Targeting gene expression to protect mucosal surfaces from virus induced diseases.
Name of the conference: Fifth International Symposium Positive Strand RNA Viruses.
City of event: St. Petersburg, United States of America
Date of event: 1998
End date: 1998
Organising entity: International society of virology
L Enjuanes; I Sola; J Castilla; Z Penzes; A Izeta; JM Sanchez-Morgado; JM Gonzalez; S Alonso; M Muntion; D Escors; C Sanchez.

- 91** **Title of the work:** Protection of coronavirus infection by expressing recombinant virus neutralizing antibodies
Name of the conference: 8th European Congress on Biotechnology
City of event: Budapest, Hungary
Date of event: 1997
End date: 1997
Organising entity: European society of Biotechnology
I Sola; J Castilla; D Escors; L Enjuanes.
- 92** **Title of the work:** Interference with PD-L1/PD-1 co-stimulation results in effective anti-tumour immunity by preventing ligand-induced T cell receptor down-modulation in effector CD8 T cells
Name of the conference: ESGCT congress
City of event: Madrid, Spain
Organising entity: ESGCT
David Escors Murugarren; Therese Liechtenstein; Noemi Perez Janices; Alessio Lanna; Christopher Bricogne; Katarzyna Karwacz; David Guerrero Setas; Karine Breckpot.

R&D management and participation in scientific committees

Scientific, technical and/or assessment committees

- 1** **Committee title:** PhD Thesis tribunal
Affiliation entity: University of Navarre
Start-End date: 09/02/2016 - 09/02/2016
- 2** **Committee title:** PhD Thesis tribunal
Affiliation entity: University of Navarre
Start-End date: 09/02/2016 - 09/02/2016
- 3** **Committee title:** PhD Thesis tribunal
Affiliation entity: University of Navarre
Start-End date: 19/09/2015 - 19/09/2015
- 4** **Committee title:** PhD Thesis tribunal
Affiliation entity: Free University of Brussels
Start-End date: 03/09/2015 - 03/09/2015
- 5** **Committee title:** PhD Thesis tribunal
Affiliation entity: Autonomous University of Madrid
Start-End date: 26/06/2015 - 26/06/2015
- 6** **Committee title:** PhD thesis tribunal
Affiliation entity: University of Navarre
Start-End date: 13/12/2014 - 13/12/2014
- 7** **Committee title:** RefBio
Affiliation entity: European Union
City affiliation entity: Brussels,



Start-End date: 2013 - 2014

- 8** **Committee title:** Fonds Wetenschappelijk Onderzoek (FWO), Belgium
Primary (UNESCO code): 240000 - Life Science
Affiliation entity: Gobierno de Bruselas **Type of entity:** State agency
City affiliation entity: Belgium
Start-End date: 2008 - 2013
- 9** **Committee title:** National Research Foundation
Affiliation entity: Gobierno de Sudafrica
City affiliation entity: South African Republic
End date: 2013
- 10** **Committee title:** National Science Centre
Affiliation entity: Gobierno de Polonia
City affiliation entity: Poland
End date: 2013
- 11** **Committee title:** PhD thesis tribunal
Affiliation entity: Free University of Brussels **Type of entity:** University
City affiliation entity: Brussels,
Start-End date: 13/12/2012 - 13/12/2012
- 12** **Committee title:** British Medical Research Council (MRC) Reviewer panel
Primary (UNESCO code): 320000 - Medical Science
Affiliation entity: British Medical Research Council **Type of entity:** State agency
City affiliation entity: United Kingdom
Start-End date: 2012 - 2012
- 13** **Committee title:** NUTRITHERAGENE
Primary (UNESCO code): 240000 - Life Science
Affiliation entity: Agence Nationale de la Recherche **Type of entity:** State agency
City affiliation entity: France
Start-End date: 2012 - 2012
- 14** **Committee title:** PhD Thesis tribunal
Affiliation entity: University of Navarre **Type of entity:** University
Start date: 22/09/2017
- 15** **Committee title:** PhD Thesis tribunal
Affiliation entity: University of Navarre
Start date: 03/10/2016

**C****V****N**

CURRÍCULUM VITAE NORMALIZADO

13a4ea0fa02b5f79006b853171b41a11

Organization of R&D activities

Title of the activity: Ramón Areces Symposium

Type of activity: Chair

Geographical area: Non EU International

Convening entity: Fundación Ramón Areces

Type of entity: Foundation

City convening entity: Pamplona, Foral Community of Navarre, Spain

Start-End date: 29/10/2017 - 31/10/2017